113. Muscular dystrophy Disease details / Clinical trials / Drug dev / DR info

Clinical trials : 646 /  Drugs : 471 - (DrugBank : 105) / Drug target genes : 59 - Drug target pathways : 170

Drugs and their primary sponsors and trial info
(+)- Epicatechin   
   Craig McDonald, MD
      2016   Phase 1/Phase 2   NCT02964377   United States;
(+)-Epicatechin   
   Epirium Bio Inc.
      2020   Phase 1   NCT04386304   United States;
(-)-Epicatechin   
   Craig McDonald, MD
      2016   Phase 2   NCT03236662   United States;
(-)-epicatechin   
   Craig McDonald, MD
      2013   Phase 1/Phase 2   NCT01856868   United States;
/kg GSK2402968   
   GlaxoSmithKline
      2010   Phase 1   NCT01128855   France;United States;
2011-2012 seasonal flu vaccine Intramuscular   
   Children's Hospital Medical Center, Cincinnati
      2011   Phase 4   NCT01422200   United States;
2011-2012 seasonal flu vaccine Subcutaneous   
   Children's Hospital Medical Center, Cincinnati
      2011   Phase 4   NCT01422200   United States;
29180.00.00, 34681.00.00, 34681.01.00, 34681.02.00   
   Universitätsklinik Freiburg
      2005   Phase 2;Phase 3   EUCTR2005-000663-26-AT   Austria;
4-Benzyl-2-naphthalen-1-yl-1,2,4- thiadiazolidine-3,5-dione   
   AMO Pharma Ltd.
      2016   Phase 2   EUCTR2016-000067-16-GB   United Kingdom;
4-benzyl-2-naphthalen-1-yl-1,2,4-thiadiazolidine-3,5-dione   
   AMO Pharma Ltd
      2018   Phase 2;Phase 3   EUCTR2016-004623-23-GB   Canada;United Kingdom;United States;
5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole   
   Summit Corporation plc
      2013   Phase 1   EUCTR2013-002115-99-GB   United Kingdom;
AAV1-gamma-sarcoglycan vector injection   
   Genethon
      2006   Phase 1   NCT01344798   France;
ACE-031 (Extension of cohort 1 from core study, A031-03)   
   Acceleron Pharma, Inc.
      2010   Phase 2   NCT01239758   Canada;
ACE-031 (Extension of cohort 2 from core study, A031-03)   
   Acceleron Pharma, Inc.
      2010   Phase 2   NCT01239758   Canada;
ACE-031 (Extension of cohort 3 from core study, A031-03)   
   Acceleron Pharma, Inc.
      2010   Phase 2   NCT01239758   Canada;
ACE-031 0.5 mg/kg q4wk   
   Acceleron Pharma, Inc.
      2010   Phase 2   NCT01099761   Canada;
ACE-031 1.0 mg/kg q2wk   
   Acceleron Pharma, Inc.
      2010   Phase 2   NCT01099761   Canada;
ACE-083   
   Acceleron Pharma Inc.
      2019   Phase 2   EUCTR2019-000305-79-ES   Canada;Spain;United States;
      2018   Phase 2   EUCTR2016-003257-15-ES   Canada;Spain;United States;
   Acceleron Pharma, Inc.
      2019   Phase 2   NCT03943290   Canada;Spain;United States;
      2016   Phase 2   NCT02927080   Canada;Spain;United States;
ADENO-ASSOCIATED VIRUS SEROTYPE RH74 CONTAINING THE HUMAN MICRO-DYSTROPHIN GENE   
   Sarepta Therapeutics, Inc.
      2022   Phase 3   EUCTR2019-003374-91-ES   Belgium;France;Germany;Hong Kong;Italy;Japan;Spain;Taiwan;United Kingdom;United States;
AOC 1001   
   Avidity Biosciences, Inc.
      2021   Phase 1/Phase 2   NCT05027269   United States;
ATYR1940   
   ATYR PHARMA, INC.
      -   Phase 1;Phase 2   EUCTR2016-000624-25-IT   Denmark;Italy;
      -   Phase 1;Phase 2   EUCTR2014-003346-27-IT   France;Italy;United States;
   aTyr Pharma, Inc.
      2016   Phase 1;Phase 2   EUCTR2016-000624-25-DK   Denmark;Italy;United States;
      2016   Phase 1/Phase 2   NCT02836418   Denmark;Italy;United States;
      2016   Phase 1/Phase 2   NCT02603562   France;Italy;United States;
      2015   Phase 1;Phase 2   EUCTR2015-001912-36-NL   Italy;Netherlands;United States;
      2015   Phase 1;Phase 2   EUCTR2015-001910-88-DK   Denmark;France;Italy;United States;
      2015   Phase 1/Phase 2   NCT02579239   Denmark;France;Italy;United States;
      2015   Phase 1/Phase 2   NCT02531217   Italy;Netherlands;United States;
      2014   Phase 1;Phase 2   EUCTR2014-001753-17-IT   France;Italy;Netherlands;United States;
      2014   Phase 1/Phase 2   NCT02239224   France;Italy;Netherlands;United States;
      2014   -   EUCTR2014-001753-17-NL   France;Italy;Netherlands;United States;
AVI-4658   
   AVI BioPharma, Inc.
      2008   -   EUCTR2007-004695-39-GB   United Kingdom;
   Imperial College, London
      2007   Phase 1;Phase 2   EUCTR2006-003833-33-GB   United Kingdom;
   SAREPTA THERAPEUTICS, INC.
      2019   Phase 2   EUCTR2019-000337-39-IT   Belgium;France;Italy;United Kingdom;
      2017   Phase 2   EUCTR2016-000951-29-IT   Belgium;France;Germany;Italy;United Kingdom;
   Sarepta Therapeutics, Inc
      2019   Phase 2   EUCTR2019-000337-39-GB   Belgium;France;United Kingdom;
      2019   Phase 2   EUCTR2019-000337-39-BE   Belgium;France;United Kingdom;
      2017   Phase 2   EUCTR2016-000951-29-BE   Belgium;France;Germany;Italy;United Kingdom;
      2017   Phase 1   EUCTR2016-000951-29-FR   Belgium;France;Germany;Italy;United Kingdom;
      -   Phase 2   EUCTR2019-000337-39-FR   Belgium;France;United Kingdom;
   Sarepta Therapeutics, Inc.
      2022   Phase 3   EUCTR2018-001762-42-NO   Australia;Canada;Colombia;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2022   Phase 3   EUCTR2018-001762-42-GR   Australia;Belgium;Canada;Colombia;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-001762-42-SE   Argentina;Australia;Belgium;Canada;Chile;Colombia;Denmark;France;Germany;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Peru;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-001762-42-NL   Australia;Belgium;Canada;Colombia;Czechia;Denmark;France;Germany;Ireland;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-001762-42-IE   Australia;Belgium;Canada;Colombia;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-001762-42-DE   Australia;Belgium;Canada;Colombia;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-001762-42-GB   Australia;Belgium;Canada;Colombia;Czechia;Denmark;France;Germany;Ireland;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-001762-42-ES   Argentina;Australia;Belgium;Canada;Chile;Colombia;France;Germany;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;Peru;Russian Federation;Spain;Taiwan;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2018-001762-42-DK   Australia;Belgium;Canada;Colombia;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-000951-29-GB   Belgium;France;Germany;Italy;United Kingdom;
      2017   Phase 2   EUCTR2016-000951-29-DE   Belgium;France;Germany;Italy;United Kingdom;
      -   Phase 3   EUCTR2018-001762-42-FR   Argentina;Australia;Belgium;Canada;Chile;Colombia;France;Germany;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Peru;Russian Federation;Spain;Taiwan;Turkey;United Kingdom;
      -   Phase 3   EUCTR2016-005002-19-Outside-EU/EEA   United States;
      -   Phase 2   EUCTR2016-005024-28-Outside-EU/EEA   United States;
      -   Phase 2   EUCTR2016-005023-92-Outside-EU/EEA   United States;
      -   Phase 2   EUCTR2016-005001-39-Outside-EU/EEA   United States;
      -   Phase 2   EUCTR2016-005000-26-Outside-EU/EEA   United States;
AVI-4658 (Eteplirsen)   
   Sarepta Therapeutics, Inc.
      2012   Phase 2   NCT01540409   United States;
      2011   Phase 2   NCT01396239   United States;
AVI-4658 (PMO)   
   Imperial College London
      2007   Phase 1/Phase 2   NCT00159250   United Kingdom;
AVI-4658 for Injection   
   Sarepta Therapeutics
      2009   Phase 1/Phase 2   NCT00844597   United Kingdom;
Activity Monitor   
   Pfizer
      2020   -   NCT04254172   United States;
Actonel Once a week 5mg film coated tablets   
   The Central Remedial Clinic and The Children's University Hospital
      2010   -   EUCTR2009-017649-67-IE   Ireland;
Adeno-associated viral vector serotype 8 containing the human MD1 gene   
   Genethon
      2020   Phase 1;Phase 2;Phase 3   EUCTR2020-002093-27-FR   France;Israel;United Kingdom;United States;
Adeno-associated viral vector serotype 9 containing the human mini-dystrophin gene   
   Pfizer Inc.
      2021   Phase 3   EUCTR2019-002921-31-FR   Belgium;Canada;China;France;Germany;Israel;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-002921-31-BE   Belgium;Canada;China;France;Germany;Israel;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002921-31-GB   Belgium;Canada;China;France;Germany;Israel;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
Adeno-associated virus serotype 9 carrying the human fukutin-related protein and target sequence of the miR-208a   
   Atamyo Therapeutics
      2022   Phase 1;Phase 2   EUCTR2021-004276-33-DK   Canada;Denmark;France;Germany;Norway;Sweden;United Kingdom;United States;
Albuterol   
   Ohio State University
      1998   -   NCT00004685   -
Allogeneic Cardiosphere-Derived Cells (CAP-1002)   
   Capricor Inc.
      2016   Phase 1/Phase 2   NCT02485938   United States;
Anti-Myostatin Adnectin   
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 3   EUCTR2016-001654-18-IT   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
   Bristol-Myers Squibb International Corporation
      2017   Phase 3   EUCTR2016-001654-18-FR   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001654-18-ES   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd
      2017   Phase 3   EUCTR2016-001654-18-NL   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001654-18-GB   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
Anti-myostati   
   F. Hoffmann-La Roche Ltd
      2017   Phase 3   EUCTR2016-001654-18-BE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
Anti-myostatin Adnectin   
   F. Hoffmann-La Roche Ltd
      2017   Phase 3   EUCTR2016-001654-18-SE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001654-18-DE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001654-18-BE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
Aspirin   
   Kobe University Graduate School of Medicine
      2012   Phase 1,2   JPRN-UMIN000009307   Japan;
   National Hospital Organization Toneyama National Hospital
      2014   -   JPRN-UMIN000016092   Japan;
Ataluren   
   PTC THERAPEUTICS, INC.
      2012   Phase 3   EUCTR2011-004853-18-IT   Australia;Belgium;Canada;Germany;Israel;Italy;Spain;Sweden;United Kingdom;
   PTC Therapeutics
      2021   Phase 2   NCT04336826   United States;
      2019   Phase 2   NCT03796637   United States;
      2018   Phase 2   NCT03648827   United States;
      2017   Phase 3   NCT03179631   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Hong Kong;India;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Poland;Puerto Rico;Russian Federation;Sri Lanka;Taiwan;Thailand;Turkey;United States;
      2016   Phase 2   NCT02819557   United States;
      2014   Phase 3   NCT02090959   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Czechia;France;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   NCT01826487   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Czechia;France;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   NCT01557400   Australia;Belgium;Canada;France;Germany;Israel;Italy;Spain;Sweden;United Kingdom;
      2010   Phase 3   NCT01247207   Canada;United States;
      2010   Phase 2   NCT01009294   United Kingdom;United States;
      2009   Phase 2   NCT00847379   Australia;Belgium;Canada;France;Germany;Israel;Italy;Spain;Sweden;United Kingdom;United States;
      2008   Phase 2   NCT00759876   United States;
      2008   Phase 2   NCT00592553   Australia;Belgium;Canada;France;Germany;Israel;Italy;Spain;Sweden;United Kingdom;United States;
   PTC Therapeutics, Inc
      2014   -   EUCTR2012-004527-20-PL   Australia;Belgium;Brazil;Canada;Chile;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-004527-20-SE   Australia;Belgium;Brazil;Canada;Chile;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-004527-20-GB   Australia;Belgium;Brazil;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-004527-20-DE   Australia;Belgium;Brazil;Canada;Chile;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-004527-20-CZ   Australia;Belgium;Brazil;Canada;Chile;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-004527-20-BE   Australia;Belgium;Brazil;Canada;Chile;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-004527-20-IT   Australia;Belgium;Brazil;Canada;Chile;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-004527-20-ES   Australia;Belgium;Brazil;Canada;Chile;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-004853-18-SE   Australia;Belgium;Canada;Germany;Israel;Italy;Spain;Sweden;United Kingdom;
      2012   Phase 3   EUCTR2011-004853-18-FR   Australia;Belgium;Canada;France;Germany;Israel;Italy;Spain;Sweden;United Kingdom;
      2012   Phase 3   EUCTR2011-004853-18-ES   Australia;Belgium;Canada;Germany;Israel;Italy;Spain;Sweden;United Kingdom;
      2012   Phase 3   EUCTR2011-004853-18-BE   Australia;Belgium;Canada;Germany;Israel;Italy;Spain;Sweden;United Kingdom;
      -   Phase 3   EUCTR2012-004527-20-FR   Australia;Belgium;Brazil;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   PTC Therapeutics, Inc.
      2016   Phase 3   EUCTR2013-005489-20-FR   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2015   Phase 3   EUCTR2013-005489-20-CZ   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2015   Phase 3   EUCTR2013-005489-20-BG   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005489-20-SE   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005489-20-IT   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005489-20-GB   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005489-20-ES   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005489-20-DE   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005489-20-BE   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-004853-18-GB   Australia;Belgium;Canada;France;Germany;Israel;Italy;Spain;Sweden;United Kingdom;
      2012   Phase 3   EUCTR2011-004853-18-DE   Australia;Belgium;Canada;Germany;Israel;Italy;Spain;Sweden;United Kingdom;
      2009   Phase 2   EUCTR2007-005478-29-GB   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-005478-29-SE   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-005478-29-DE   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-005478-29-BE   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom;
      -   Phase 2   EUCTR2020-000980-21-Outside-EU/EEA   United States;
   Penematsa Vinay
      2021   Phase 3   JPRN-jRCT2041200087   China;Japan;
Autologous bone marrow mononuclear cell transplantation   
   Neurogen Brain and Spine Institute
      2008   Phase 1   NCT02050776   India;
BBP-418   
   ML Bio Solutions, Inc.
      2021   Phase 2   NCT04800874   United States;
BIO101   
   Biophytis
      2020   Phase 1   EUCTR2019-004602-94-BE   Belgium;
BLS-M22   
   BioLeaders Corporation
      2019   Phase 1   NCT03789734   Korea, Republic of;
BMN 044   
   BIOMARIN PHARMACEUTICAL INC.
      -   Phase 2   EUCTR2015-003681-87-IT   Belgium;Italy;Netherlands;Sweden;United States;
   BioMarin Pharmaceutical Inc.
      2016   Phase 2   EUCTR2015-003681-87-BE   Belgium;Italy;Netherlands;Sweden;United States;
BMN 044 IV   
   BioMarin Pharmaceutical
      2016   Phase 2   NCT02958202   Belgium;Italy;Netherlands;Sweden;
BMN 044 SC   
   BioMarin Pharmaceutical
      2016   Phase 2   NCT02958202   Belgium;Italy;Netherlands;Sweden;
BMN 045   
   BioMarin Pharmaceutical Inc.
      2013   Phase 1;Phase 2   EUCTR2011-005040-10-GB   Belgium;France;Italy;United Kingdom;
BMN 053   
   BioMarin Pharmaceutical Inc.
      2013   Phase 1;Phase 2   EUCTR2011-005042-35-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Turkey;United Kingdom;United States;
BMN053   
   BioMarin Nederland B.V.
      2013   Phase 1;Phase 2   EUCTR2011-005042-35-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Turkey;United Kingdom;United States;
BMS-986089-01 (RO7239361) , anti-myostatin   
   F. Hoffmann-La Roche Ltd
      2017   Phase 3   EUCTR2016-001654-18-BE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
BMS-986089-01 (RO7239361) Injections, 15 mg/Syringe (21.4 mg/mL)   
   F. Hoffmann-La Roche Ltd
      2017   Phase 3   EUCTR2016-001654-18-BE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
BMS-986089-01 (RO7239361) Injections, 35 mg/Syringe (50 mg/mL)   
   F. Hoffmann-La Roche Ltd
      2017   Phase 3   EUCTR2016-001654-18-BE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
BMS-986089-01 (RO7239361) Injections, 50 mg/Syringe (71.4 mg/mL)   
   F. Hoffmann-La Roche Ltd
      2017   Phase 3   EUCTR2016-001654-18-BE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
BMS-986089-01 (RO7239361) Injections, 7.5 mg/Syringe (10.7 mg/mL)   
   F. Hoffmann-La Roche Ltd
      2017   Phase 3   EUCTR2016-001654-18-BE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
BMS-986089-01 (RO7239361), anti-myostatin   
   F. Hoffmann-La Roche Ltd
      2017   Phase 3   EUCTR2016-001654-18-BE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
BMS-986089-01 Injections, 15 mg/Syringe (21.4 mg/mL)   
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 3   EUCTR2016-001654-18-IT   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
   Bristol-Myers Squibb International Corporation
      2017   Phase 3   EUCTR2016-001654-18-FR   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001654-18-ES   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
BMS-986089-01 Injections, 35 mg/Syringe (50 mg/mL)   
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 3   EUCTR2016-001654-18-IT   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
   Bristol-Myers Squibb International Corporation
      2017   Phase 3   EUCTR2016-001654-18-FR   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001654-18-ES   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
BMS-986089-01 Injections, 50 mg/Syringe (71.4 mg/mL)   
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 3   EUCTR2016-001654-18-IT   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
   Bristol-Myers Squibb International Corporation
      2017   Phase 3   EUCTR2016-001654-18-FR   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
BMS-986089-01 Injections, 7.5 mg/Syringe (10.7 mg/mL)   
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 3   EUCTR2016-001654-18-IT   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
   Bristol-Myers Squibb International Corporation
      2017   Phase 3   EUCTR2016-001654-18-FR   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001654-18-ES   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
BMS-986089-01, anti-myostatin   
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 3   EUCTR2016-001654-18-IT   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
   Bristol-Myers Squibb International Corporation
      2017   Phase 3   EUCTR2016-001654-18-FR   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001654-18-ES   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd
      2017   Phase 3   EUCTR2016-001654-18-DE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
Balance   
   Prof. Dr. Benedikt Schoser
      2018   -   NCT03603171   Germany;
Betaloc ZOK 100,   
   Medical University of Gdansk
      2021   Phase 3   EUCTR2020-004901-29-PL   Poland;
Betaloc ZOK 25, 23,   
   Medical University of Gdansk
      2021   Phase 3   EUCTR2020-004901-29-PL   Poland;
Bisoprolol   
   Newcastle upon Tyne Hospitals NHS Foundation Trust
      2009   Phase 3   EUCTR2007-005932-10-GB   United Kingdom;
Bisoprolol Fumarate   
   Peking Union Medical College Hospital
      2019   Phase 2/Phase 3   NCT03779646   China;
Bisphosphonate treatment   
   Gilles Boire
      2001   Phase 4   NCT01882400   Canada;
Blood test   
   Centre Hospitalier Universitaire de Nice
      2013   -   NCT01970735   France;
Bocidelpar   
   Astellas Pharma Inc
      2021   Phase 1   NCT04184882   United States;
CAP-1002   
   Capricor Inc.
      2022   Phase 3   NCT05126758   United States;
      2020   Phase 2   NCT04428476   United States;
      2018   Phase 2   NCT03406780   United States;
CAT-1004   
   Catabasis Pharmaceuticals Inc.
      2020   Phase 3   EUCTR2019-003563-22-SE   Australia;Canada;Germany;Ireland;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-003563-22-IE   Australia;Canada;Germany;Ireland;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-003563-22-GB   Australia;Canada;Germany;Ireland;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-003563-22-DE   Australia;Canada;Germany;Ireland;Israel;Sweden;United Kingdom;United States;
   Catabasis Pharmaceuticals, Inc.
      2019   Phase 3   EUCTR2018-000464-29-IE   Australia;Canada;Germany;Ireland;Israel;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-000464-29-DE   Australia;Canada;Germany;Ireland;Israel;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000464-29-SE   Australia;Canada;Germany;Ireland;Israel;Sweden;United Kingdom;United States;
CRD007   
   Cardoz AB
      2012   Phase 2   NCT01540604   Sweden;
      2011   -   EUCTR2011-004667-76-SE   Sweden;
Cabaletta   
   Bioblast Pharma Ltd.
      2014   Phase 2   NCT02015481   Canada;Israel;United States;
Calcichew D3 Forte   
   The Central Remedial Clinic and The Children's University Hospital
      2010   -   EUCTR2009-017649-67-IE   Ireland;
Canakinumab Injection [Ilaris]   
   Children's National Research Institute
      2019   Phase 1/Phase 2   NCT03936894   United States;
Cardicor (Merck brand)   
   Newcastle upon Tyne Hospitals NHS Foundation Trust
      2009   Phase 3   EUCTR2007-005932-10-GB   United Kingdom;
Cardiovascular profile   
   Monica Levy Andersen
      2013   -   NCT01921374   Brazil;
Carvedilol   
   Catholic University, Italy
      2008   Phase 4   NCT00819845   Italy;
   POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
      2008   -   EUCTR2008-007236-18-IT   Italy;
   Suzuka Hospital
      2007   Phase 4   NCT00606775   Japan;
Casimersen   
   Kevin Flanigan
      2020   Phase 2   NCT04179409   United States;
   Sarepta Therapeutics, Inc.
      2020   Phase 3   EUCTR2015-002069-52-IE   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2015-002069-52-DK   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States;
      2018   Phase 3   NCT03532542   Belgium;Bulgaria;Canada;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2015-002069-52-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-002069-52-DE   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-002069-52-CZ   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-002069-52-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
Chronic Corticosteroid Therapy   
   PTC Therapeutics
      2010   Phase 2   NCT01009294   United Kingdom;United States;
Cialis 10 mg film-coated tablets   
   Eli Lilly and Company
      2013   Phase 3   EUCTR2013-001194-25-GB   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2013-001194-25-NL   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2013-001194-25-IT   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2013-001194-25-DE   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2013-001194-25-BE   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States;
   Lilly S.A.
      2013   Phase 3   EUCTR2013-001194-25-ES   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States;
Cialis 2.5 mg film-coated tablets   
   Eli Lilly and Company
      2013   Phase 3   EUCTR2013-001194-25-GB   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2013-001194-25-NL   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2013-001194-25-IT   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2013-001194-25-DE   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2013-001194-25-BE   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States;
   Lilly S.A.
      2013   Phase 3   EUCTR2013-001194-25-ES   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States;
Cialis 20 mg film-coated tablets   
   Eli Lilly and Company
      2013   Phase 3   EUCTR2013-001194-25-GB   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2013-001194-25-NL   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2013-001194-25-IT   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2013-001194-25-DE   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2013-001194-25-BE   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States;
   Lilly S.A.
      2013   Phase 3   EUCTR2013-001194-25-ES   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States;
Cialis 5 mg film-coated tablets   
   Eli Lilly and Company
      2013   Phase 3   EUCTR2013-001194-25-GB   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2013-001194-25-NL   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2013-001194-25-IT   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2013-001194-25-DE   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2013-001194-25-BE   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States;
   Lilly S.A.
      2013   Phase 3   EUCTR2013-001194-25-ES   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States;
Coenzyme Q10   
   Cooperative International Neuromuscular Research Group
      2007   Phase 3   NCT00308113   Australia;Puerto Rico;United States;
      2001   Phase 2   NCT00033189   United States;
Coenzyme Q10 and Lisinopril   
   Cooperative International Neuromuscular Research Group
      2010   Phase 2/Phase 3   NCT01126697   Canada;Japan;United States;
Cosintropina acetato   
   MALLINCKRODT ARD INC.
      2018   Phase 2   EUCTR2017-004139-35-IT   Bulgaria;Canada;Costa Rica;India;Ireland;Israel;Italy;Mexico;Poland;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States;
Cosyntropin   
   Mallinckrodt ARD LLC
      2018   Phase 2   NCT03400852   Bulgaria;Israel;Italy;Mexico;Serbia;Spain;Turkey;United States;
Cosyntropin acetate   
   MALLINCKRODT ARD INC.
      2018   Phase 2   EUCTR2017-004139-35-IT   Bulgaria;Canada;Costa Rica;India;Ireland;Israel;Italy;Mexico;Poland;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States;
   Mallinckrodt ARD Inc.
      2018   Phase 2   EUCTR2017-004139-35-ES   Argentina;Belgium;Bulgaria;Canada;Chile;Germany;Israel;Italy;Netherlands;Serbia;Spain;Turkey;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-004139-35-BG   Argentina;Belgium;Bulgaria;Canada;Chile;Germany;Israel;Italy;Netherlands;Serbia;Spain;Turkey;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-004139-35-BE   Argentina;Belgium;Canada;Chile;Germany;Israel;Italy;Netherlands;Serbia;Spain;Turkey;United Kingdom;United States;
Cr13C   
   Radboud University Nijmegen Medical Center
      2007   -   EUCTR2006-006776-37-NL   Netherlands;
Creatine Monohydrate   
   Cooperative International Neuromuscular Research Group
      2000   Phase 2/Phase 3   NCT00016653   Belgium;Israel;Puerto Rico;United States;
Creatine monohydrate   
   National Center for Research Resources (NCRR)
      2001   Phase 3   NCT00018109   United States;
Creatine-13C   
   Radboud University Nijmegen Medical Center
      2007   -   EUCTR2006-006776-37-NL   Netherlands;
Cyclosporin A   
   Universitätsklinik Freiburg
      2005   Phase 2;Phase 3   EUCTR2005-000663-26-AT   Austria;
DEFLAN*10CPR   
   AZIENDA OSPEDALIERA DI PADOVA
      2013   -   EUCTR2010-023744-33-IT   Canada;Italy;United Kingdom;United States;
DELTACORTENE*20CPR   
   AZIENDA OSPEDALIERA DI PADOVA
      2013   -   EUCTR2010-023744-33-IT   Canada;Italy;United Kingdom;United States;
DILATREND   
   POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
      2008   -   EUCTR2008-007236-18-IT   Italy;
DRISAPERSEN SODIUM   
   BioMarin Pharmaceutical Inc.
      2016   Phase 3   EUCTR2015-001955-54-DE   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;Uruguay;
      2016   Phase 3   EUCTR2015-001955-54-BE   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;Uruguay;
      2016   Phase 3   EUCTR2014-005296-81-BE   Australia;Belgium;Canada;Czech Republic;France;Germany;Israel;Italy;Japan;Poland;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-001955-54-ES   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;Uruguay;
DS-5141b   
   Daiichi Sankyo Co., Ltd.
      2020   Phase 2   NCT04433234   Japan;
      2015   Phase 1/Phase 2   NCT02667483   Japan;
Decortin   
   Universitätsklinik Freiburg
      2005   Phase 2;Phase 3   EUCTR2005-000663-26-AT   Austria;
Deflazacort   
   AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
      2020   Phase 2   EUCTR2019-004426-24-IT   Italy;
   PTC Therapeutics
      2019   Phase 3   NCT03783923   Canada;Denmark;France;Germany;Norway;Russian Federation;Sweden;United States;
      2019   -   NCT02592941   United States;
      2018   Phase 3   NCT03642145   United States;
      2014   Phase 1   NCT02295748   United States;
      2014   Phase 1   NCT02251600   United States;
   University of Rochester
      2013   Phase 3   NCT01603407   Canada;Germany;Italy;United Kingdom;United States;
   University of Sao Paulo
      2013   -   NCT04740554   -
Deflazacort 6 mg Tablets   
   University of Rochester
      2012   -   EUCTR2010-023744-33-GB   Canada;Germany;Italy;United Kingdom;United States;
Dehydroepiandrosterone 100 and   
   University of Versailles
      2004   Phase 2/Phase 3   NCT00167609   France;
Dexmedetomidine   
   Nationwide Children's Hospital
      2011   -   NCT01645098   United States;
Dosing Extension   
   BioMarin Pharmaceutical
      2013   Phase 1/Phase 2   NCT01957059   Belgium;France;Italy;Netherlands;United Kingdom;
Drisapersen   
   BioMarin Nederland BV
      2015   Phase 3   EUCTR2015-001955-54-NL   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;Uruguay;
   BioMarin Pharmaceutical
      2015   -   NCT02636686   Argentina;Australia;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   NCT01803412   Canada;United States;
      2008   Phase 2   NCT01910649   -
   GlaxoSmithKline
      2014   Phase 3   NCT01890798   -
   Prosensa Therapeutics BV
      2008   Phase 1;Phase 2   EUCTR2007-004819-54-SE   Belgium;Netherlands;Sweden;
      2008   Phase 1;Phase 2   EUCTR2007-004819-54-BE   Belgium;Netherlands;Sweden;
EDG-5506   
   Edgewise Therapeutics, Inc.
      2021   Phase 1   NCT05160415   United States;
      2020   Phase 1   NCT04585464   United States;
EMD 87580   
   ESPERARE FOUNDATION
      2017   Phase 1   EUCTR2015-002530-50-IT   France;Italy;Spain;United Kingdom;
   EspeRare
      2015   Phase 1   EUCTR2015-002530-50-GB   France;Italy;Spain;Switzerland;United Kingdom;
      2015   Phase 1   EUCTR2015-002530-50-FR   France;Italy;Spain;Switzerland;United Kingdom;
      2015   Phase 1   EUCTR2015-002530-50-ES   France;Italy;Spain;Switzerland;United Kingdom;
EMEA/H/C/000638   
   Rigshospitalet
      2011   -   EUCTR2010-024659-10-DK   Denmark;
EMFLAZA® (DEFLAZACORT)   
   PTC Therapeutics, Inc.
      2019   Phase 3   EUCTR2018-004740-36-FR   Canada;Denmark;France;Germany;Norway;Sweden;United States;
      2019   Phase 3   EUCTR2018-004740-36-DK   Canada;Denmark;France;Germany;Norway;Russian Federation;Sweden;United States;
      2019   Phase 3   EUCTR2018-004740-36-DE   Canada;Denmark;France;Germany;Norway;Russian Federation;Sweden;United States;
EMFLAZA® (deflazacort)   
   PTC Therapeutics, Inc.
      2019   Phase 3   EUCTR2018-004740-36-FR   Canada;Denmark;France;Germany;Norway;Sweden;United States;
      2019   Phase 3   EUCTR2018-004740-36-DK   Canada;Denmark;France;Germany;Norway;Russian Federation;Sweden;United States;
      2019   Phase 3   EUCTR2018-004740-36-DE   Canada;Denmark;France;Germany;Norway;Russian Federation;Sweden;United States;
EPA and DHA   
   Coordinación de Investigación en Salud, Mexico
      2013   -   NCT01826422   Mexico;
ERX-963   
   Expansion Therapeutics, Inc.
      2019   Phase 1   NCT03959189   United States;
EV substance code: SUB188638   
   ReveraGen BioPharma Inc.
      2018   Phase 2   EUCTR2017-003568-10-GB   Australia;Canada;Israel;Sweden;United Kingdom;United States;
EXONDYS 51™   
   Sarepta Therapeutics, Inc.
      -   Phase 3   EUCTR2016-005002-19-Outside-EU/EEA   United States;
      -   Phase 2   EUCTR2016-005024-28-Outside-EU/EEA   United States;
      -   Phase 2   EUCTR2016-005023-92-Outside-EU/EEA   United States;
Edasalonexent   
   Catabasis Pharmaceuticals
      2019   Phase 3   NCT03917719   Australia;Canada;Germany;Sweden;United Kingdom;United States;
      2018   Phase 3   NCT03703882   Australia;Canada;Germany;Ireland;Israel;Sweden;United Kingdom;United States;
      2016   Phase 1/Phase 2   NCT02439216   United States;
   Catabasis Pharmaceuticals, Inc.
      2019   Phase 3   EUCTR2018-000464-29-IE   Australia;Canada;Germany;Ireland;Israel;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000464-29-SE   Australia;Canada;Germany;Ireland;Israel;Sweden;United Kingdom;United States;
EnaHexal®,   
   Friedrich- Alexander- Universität Erlangen Nürnberg
      -   -   EUCTR2009-009871-36-DE   Germany;
EnalHexal®,   
   Friedrich- Alexander- Universität Erlangen Nürnberg
      -   -   EUCTR2009-009871-36-DE   Germany;
Enalapril   
   InCor Heart Institute
      2009   Phase 3   NCT02432885   -
Epigallocatechin-Gallate   
   Charite University, Berlin, Germany
      2010   Phase 2/Phase 3   NCT01183767   Germany;
Eplerenone   
   Ohio State University
      2015   Phase 3   NCT02354352   United States;
   Subha Raman
      2012   -   NCT01521546   United States;
Esomeprazole   
   AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
      2020   Phase 2   EUCTR2019-004426-24-IT   Italy;
Esomeprazolo   
   AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
      2020   Phase 2   EUCTR2019-004426-24-IT   Italy;
Eteplirsen   
   Kevin Flanigan
      2020   Phase 2   NCT04179409   United States;
   Sarepta Therapeutics, Inc.
      2020   Phase 3   NCT03992430   Canada;Korea, Republic of;Taiwan;United States;
      2019   Phase 2   NCT03985878   Belgium;France;Italy;United Kingdom;
      2017   Phase 2   NCT03218995   Belgium;France;Germany;Italy;United Kingdom;
      2015   Phase 2   NCT02420379   United States;
      2014   Phase 3   NCT02255552   United States;
      2014   Phase 2   NCT02286947   United States;
Eteplirsen Injection   
   Sarepta Therapeutics, Inc.
      -   Phase 3   EUCTR2016-005002-19-Outside-EU/EEA   United States;
      -   Phase 2   EUCTR2016-005024-28-Outside-EU/EEA   United States;
      -   Phase 2   EUCTR2016-005023-92-Outside-EU/EEA   United States;
      -   Phase 2   EUCTR2016-005001-39-Outside-EU/EEA   United States;
      -   Phase 2   EUCTR2016-005000-26-Outside-EU/EEA   United States;
Eucardic   
   Department Of Paediatric Cardiology
      -   Phase 4   EUCTR2006-003075-12-IE   Ireland;
Exondys 51   
   SAREPTA THERAPEUTICS, INC.
      2017   Phase 2   EUCTR2016-000951-29-IT   Belgium;France;Germany;Italy;United Kingdom;
   Sarepta Therapeutics, Inc
      2019   Phase 2   EUCTR2019-000337-39-BE   Belgium;France;United Kingdom;
      2017   Phase 1   EUCTR2016-000951-29-FR   Belgium;France;Germany;Italy;United Kingdom;
      -   Phase 2   EUCTR2019-000337-39-FR   Belgium;France;United Kingdom;
   Sarepta Therapeutics, Inc.
      2019   Phase 3   EUCTR2018-001762-42-ES   Argentina;Australia;Belgium;Canada;Chile;Colombia;France;Germany;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;Peru;Russian Federation;Spain;Taiwan;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2018-001762-42-DK   Australia;Belgium;Canada;Colombia;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2018-001762-42-FR   Argentina;Australia;Belgium;Canada;Chile;Colombia;France;Germany;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Peru;Russian Federation;Spain;Taiwan;Turkey;United Kingdom;
      -   Phase 2   EUCTR2016-005001-39-Outside-EU/EEA   United States;
      -   Phase 2   EUCTR2016-005000-26-Outside-EU/EEA   United States;
Ezutromid   
   Summit Therapeutics
      2016   Phase 2   NCT02858362   United Kingdom;United States;
FG-3019   
   FIBROGEN
      2021   Phase 3   EUCTR2020-000699-39-IT   Australia;Austria;Belgium;Canada;Czechia;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000698-26-IT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States;
   FibroGen, Inc.
      2021   Phase 3   EUCTR2020-000699-39-NL   Australia;Austria;Belgium;Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000699-39-AT   Australia;Austria;Belgium;Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000698-26-NL   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000698-26-AT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000698-26-GB   Australia;Austria;Belgium;Canada;Czech Republic;France;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States;
      -   Phase 3   EUCTR2020-000699-39-BE   Australia;Austria;Belgium;Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2020-000698-26-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2020-000698-26-BE   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
FTX-1821   
   Fulcrum Therapeutics, Inc.
      2019   Phase 2   EUCTR2019-001181-15-FR   France;Germany;Spain;United States;
      2019   Phase 2   EUCTR2019-001181-15-ES   France;Germany;Spain;United States;
Flavocoxid   
   University of Messina
      2011   Phase 1   NCT01335295   Italy;
GIVINOSTAT (hyrochloride monohydrate)   
   ITALFARMACO S.p.A.
      2020   Phase 3   EUCTR2017-000397-10-GB   Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
GNT0004   
   Genethon
      2020   Phase 1;Phase 2;Phase 3   EUCTR2020-002093-27-FR   France;Israel;United Kingdom;United States;
GNT0006   
   Atamyo Therapeutics
      2022   Phase 1;Phase 2   EUCTR2021-004276-33-DK   Canada;Denmark;France;Germany;Norway;Sweden;United Kingdom;United States;
GSK2402968   
   GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
      2012   -   EUCTR2011-001266-17-IT   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;Czech Republic;Denmark;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Turkey;United Kingdom;
   GlaxoSmithKline
      2011   Phase 3   NCT01480245   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan;Turkey;United Kingdom;
      2010   Phase 2   NCT01153932   Australia;Belgium;France;Germany;Israel;Netherlands;Spain;Turkey;United Kingdom;
   GlaxoSmithKline Research and Development LTD
      2012   Phase 3   EUCTR2011-001266-17-DK   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan;Turkey;United Kingdom;
      2012   Phase 3   EUCTR2010-020069-26-HU   Argentina;Belgium;Brazil;Canada;Chile;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan;
      2012   -   EUCTR2011-001266-17-HU   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan;Turkey;United Kingdom;
      2012   -   EUCTR2011-001266-17-CZ   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan;Turkey;United Kingdom;
      2012   -   EUCTR2011-001266-17-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan;Turkey;United Kingdom;
      2011   Phase 3   EUCTR2011-001266-17-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan;Turkey;United Kingdom;
      2011   Phase 3   EUCTR2011-001266-17-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan;Turkey;United Kingdom;
      2011   Phase 3   EUCTR2010-020069-26-BE   Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;
      2011   -   EUCTR2011-001266-17-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan;Turkey;United Kingdom;
      2011   -   EUCTR2011-001266-17-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan;Turkey;United Kingdom;
      2011   -   EUCTR2010-020069-26-PL   Argentina;Belgium;Brazil;Canada;Chile;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan;
      2011   -   EUCTR2010-020069-26-NL   Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;
      2011   -   EUCTR2010-020069-26-DK   Argentina;Belgium;Brazil;Canada;Chile;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan;
      2011   -   EUCTR2010-020069-26-CZ   Argentina;Belgium;Brazil;Canada;Chile;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan;
      2010   Phase 3   EUCTR2010-020069-26-FR   Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Norway;Poland;Spain;
      2010   Phase 2   EUCTR2010-018412-32-FR   Belgium;France;Germany;Netherlands;Spain;United Kingdom;
      2010   Phase 2   EUCTR2010-018412-32-BE   Australia;Belgium;France;Germany;Israel;Netherlands;Spain;Turkey;United Kingdom;
      2010   -   EUCTR2010-020069-26-IT   Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;
      2010   -   EUCTR2010-018412-32-NL   France;Germany;Netherlands;Spain;United Kingdom;
      2010   -   EUCTR2010-018412-32-GB   Australia;France;Germany;Israel;Netherlands;Spain;Turkey;United Kingdom;
      2010   -   EUCTR2010-018412-32-ES   France;Germany;Netherlands;Spain;United Kingdom;
      2010   -   EUCTR2010-018412-32-DE   Australia;France;Germany;Israel;Netherlands;Spain;Turkey;United Kingdom;
      -   Phase 3   EUCTR2011-001266-17-FR   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan;Turkey;United Kingdom;
      -   Phase 3   EUCTR2010-020069-26-NO   Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Norway;Poland;Spain;
      -   Phase 1   EUCTR2010-024566-22-FR   France;
      -   -   EUCTR2011-001266-17-Outside-EU/EEA   -
      -   -   EUCTR2010-024566-22-Outside-EU/EEA   United States;
      -   -   EUCTR2010-020069-26-Outside-EU/EEA   Argentina;Belgium;Brazil;Canada;Chile;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan;
      -   -   EUCTR2010-020069-26-DE   Argentina;Belgium;Brazil;Canada;Chile;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan;
      -   -   EUCTR2010-018412-32-Outside-EU/EEA   Australia;Israel;Turkey;
   GlaxoSmithKline, S.A.
      2011   -   EUCTR2011-001266-17-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan;Turkey;United Kingdom;
   GlaxoSmithKline.S.A.
      2011   Phase 3   EUCTR2010-020069-26-ES   Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Norway;Poland;Spain;
GSK2402968 3mg/kg/week   
   GlaxoSmithKline
      2011   Phase 2   NCT01462292   United States;
GSK2402968 6 mg/kg/week   
   GlaxoSmithKline
      2011   Phase 2   NCT01462292   United States;
GSK2402968 6mg/kg/week   
   GlaxoSmithKline
      2010   Phase 3   NCT01254019   Argentina;Belgium;Brazil;Canada;Chile;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan;Turkey;
Gentamicin   
   National Institute of Neurological Disorders and Stroke (NINDS)
      2000   Phase 1   NCT00005574   United States;
Gentamicin infusions twice a week for six months   
   Nationwide Children's Hospital
      2007   Phase 1   NCT00451074   United States;
Givinostat   
   ITALFARMACO
      2013   Phase 2   EUCTR2012-002566-12-IT   Italy;
   Italfarmaco
      2017   Phase 3   NCT02851797   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Serbia;Spain;United Kingdom;United States;
      2017   Phase 2/Phase 3   NCT03373968   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Serbia;Spain;United Kingdom;United States;
      2017   Phase 2   NCT03238235   Italy;Netherlands;
      2013   Phase 1/Phase 2   NCT01761292   Italy;
Givinostat (hydrochloride monohydrate)   
   ITALFARMACO S.P.A.
      2018   Phase 2   EUCTR2017-001629-41-NL   Italy;Netherlands;
      2017   Phase 2   EUCTR2017-001629-41-IT   Italy;Netherlands;
   ITALFARMACO S.p.A.
      2020   Phase 3   EUCTR2017-000397-10-GB   Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-000397-10-NL   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Serbia;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-000397-10-ES   Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-000397-10-BE   Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000401-36-NL   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Serbia;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000401-36-IT   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000401-36-GB   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Serbia;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000401-36-ES   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000401-36-DE   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000401-36-BE   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Serbia;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2017-000397-10-FR   Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2017-000397-10-DE   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Serbia;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2016-000401-36-FR   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
Givinostat (idrocloruro monoidrato)   
   ITALFARMACO S.p.A.
      2017   Phase 3   EUCTR2017-000397-10-IT   Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
Glutamine   
   Cooperative International Neuromuscular Research Group
      2000   Phase 2/Phase 3   NCT00016653   Belgium;Israel;Puerto Rico;United States;
   National Center for Research Resources (NCRR)
      2001   Phase 3   NCT00018109   United States;
Gold   
   Department of Radiology, West China Second Hospital, Sichuan University
      2018   Phase 0   ChiCTR1800018340   China;
Golodirsen   
   Kevin Flanigan
      2020   Phase 2   NCT04179409   United States;
   Sarepta Therapeutics, Inc.
      2020   Phase 3   EUCTR2015-002069-52-IE   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2015-002069-52-DK   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States;
      2018   Phase 3   NCT03532542   Belgium;Bulgaria;Canada;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2015-002069-52-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-002069-52-DE   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-002069-52-CZ   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-002069-52-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53]   
   Rare Disease Research, LLC
      2020   Phase 4   NCT04708314   United States;
Granulocyte colony-stimulating factor (Filgrastim)   
   Medical University of Bialystok
      2013   Phase 1   NCT02814110   Poland;
H44AON188   
   Prosensa Therapeutics B.V
      2010   -   EUCTR2009-013762-63-SE   Belgium;Italy;Netherlands;Sweden;
      2010   -   EUCTR2009-013762-63-NL   Belgium;Italy;Netherlands;Sweden;
      2009   Phase 1;Phase 2   EUCTR2009-013762-63-BE   Belgium;Italy;Netherlands;Sweden;
H51AON23   
   Prosensa Holding B.V.
      2008   -   EUCTR2007-004819-54-NL   Belgium;Netherlands;Sweden;
HB-adMSCs   
   Hope Biosciences Stem Cell Research Foundation
      2020   -   NCT05154851   United States;
HLA-identical allogeneic mesoangioblasts   
   FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
      2011   -   EUCTR2011-000176-33-IT   Italy;
HMABs   
   FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
      2011   -   EUCTR2011-000176-33-IT   Italy;
HT-100   
   Akashi Therapeutics
      2015   Phase 2   NCT02525302   United States;
   Processa Pharmaceuticals
      2013   Phase 2   NCT01978366   United States;
      2013   Phase 1/Phase 2   NCT01847573   United States;
Haemostasis tests   
   Assistance Publique - Hôpitaux de Paris
      2018   -   NCT03424460   France;
Hidroferol®   
   Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
      2008   -   EUCTR2007-005808-41-ES   Spain;
Hormonal profile   
   Monica Levy Andersen
      2013   -   NCT01921374   Brazil;
IGF-1   
   Children's Hospital Medical Center, Cincinnati
      2010   Phase 1/Phase 2   NCT01207908   United States;
IONIS-DMPKRx   
   Ionis Pharmaceuticals, Inc.
      2014   Phase 1/Phase 2   NCT02312011   United States;
ITF2357   
   ITALFARMACO
      2013   Phase 2   EUCTR2012-002566-12-IT   Italy;
   ITALFARMACO S.P.A.
      2018   Phase 2   EUCTR2017-001629-41-NL   Italy;Netherlands;
      2017   Phase 2   EUCTR2017-001629-41-IT   Italy;Netherlands;
   ITALFARMACO S.p.A.
      2020   Phase 3   EUCTR2017-000397-10-GB   Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-000397-10-NL   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Serbia;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-000397-10-ES   Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-000397-10-BE   Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000397-10-IT   Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000401-36-NL   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Serbia;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000401-36-IT   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000401-36-GB   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Serbia;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000401-36-ES   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000401-36-DE   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000401-36-BE   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Serbia;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2017-000397-10-FR   Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2017-000397-10-DE   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Serbia;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2016-000401-36-FR   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
ITF2357 10 mg/mL   
   Italfarmaco
      2021   Phase 1   NCT04821063   Canada;
Ibuprofen   
   Parent Project, Italy
      2011   Phase 1   NCT01478022   Italy;
Idebenone   
   Santhera Pharmaceuticals
      2013   -   NCT03433807   United States;
      2009   Phase 3   NCT01027884   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United States;
      2008   Phase 2   NCT00758225   Belgium;
      2005   Phase 2   NCT00654784   Belgium;
   Santhera Pharmaceuticals (Switzerland) Ltd
      2008   -   EUCTR2007-007752-34-BE   Belgium;
   Santhera Pharmaceuticals LLC
      2005   -   EUCTR2005-002520-33-BE   Belgium;
Idebenone 150 mg film-coated tablets   
   Santhera Pharmaceuticals
      2018   Phase 3   NCT03603288   Austria;Belgium;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States;
      2016   Phase 3   NCT02814019   Austria;Belgium;Bulgaria;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
Ifetroban   
   Cumberland Pharmaceuticals
      2020   Phase 2   NCT03340675   United States;
Increased exercise intensity   
   Cedars-Sinai Medical Center
      2013   Phase 2/Phase 3   NCT02147639   United States;
Inflammatory profile   
   Monica Levy Andersen
      2013   -   NCT01921374   Brazil;
Ketamine   
   Nationwide Children's Hospital
      2011   -   NCT01645098   United States;
L-Arginine   
   University Hospital, Basel, Switzerland
      2012   Phase 1   NCT02516085   -
L-Citrulline and Metformin & L-Citrulline   
   University Hospital, Basel, Switzerland
      2013   Phase 2   NCT02018731   Switzerland;
L-Glutamine   
   Assistance Publique - Hôpitaux de Paris
      2006   Phase 2   NCT00296621   France;
L-arginine   
   Massachusetts General Hospital
      2012   Phase 1   NCT01388764   United States;
Lentiviral Vector Trans-Skip gene modified Autologous Mesoangioblasts   
   The University of Manchester
      2019   Phase 1   EUCTR2019-001825-28-GB   United Kingdom;
Lisinopril   
   Nationwide Children's Hospital
      2009   -   NCT01982695   United States;
Lonafarnib   
   Eiger BioPharmaceuticals
      2020   -   NCT03895528   -
Losartan   
   Nationwide Children's Hospital
      2009   -   NCT01982695   United States;
Losmapimod   
   Fulcrum Therapeutics
      2020   Phase 2   NCT04264442   Canada;France;Germany;Spain;United States;
      2019   Phase 2   NCT04004000   Netherlands;
      2019   Phase 2   NCT04003974   Canada;France;Germany;Spain;United States;
Lucen   
   AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
      2020   Phase 2   EUCTR2019-004426-24-IT   Italy;
METFORMINA - 500 30 COMPRESSE   
   DIP. MEDICINA DEI SISTEMI UNIVERSITà DEGLI STUDI DI ROMA TOR VERGATA
      2019   Phase 3   EUCTR2018-000692-32-IT   Italy;
METOPROLOL SUCCINATE   
   Friedrich- Alexander- Universität Erlangen Nürnberg
      -   -   EUCTR2009-009871-36-DE   Germany;
   Medical University of Gdansk
      2021   Phase 3   EUCTR2020-004901-29-PL   Poland;
MNK-1411   
   MALLINCKRODT ARD INC.
      2018   Phase 2   EUCTR2017-004139-35-IT   Bulgaria;Canada;Costa Rica;India;Ireland;Israel;Italy;Mexico;Poland;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States;
   Mallinckrodt ARD Inc.
      2018   Phase 2   EUCTR2017-004139-35-ES   Argentina;Belgium;Bulgaria;Canada;Chile;Germany;Israel;Italy;Netherlands;Serbia;Spain;Turkey;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-004139-35-BG   Argentina;Belgium;Bulgaria;Canada;Chile;Germany;Israel;Italy;Netherlands;Serbia;Spain;Turkey;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-004139-35-BE   Argentina;Belgium;Canada;Chile;Germany;Israel;Italy;Netherlands;Serbia;Spain;Turkey;United Kingdom;United States;
MYO-029   
   Wyeth Research Division of Wyeth Pharmaceuticals Inc.
      2005   Phase 2   EUCTR2004-000622-67-GB   United Kingdom;
   Wyeth is now a wholly owned subsidiary of Pfizer
      2005   Phase 1/Phase 2   NCT00104078   United States;
MYODM   
   Myogem Health Company, S.L.
      2020   -   NCT04634682   Spain;
Mannitol   
   Toda Tatsushi
      2021   Phase 1   JPRN-jRCT2031210252   Japan;
Metabolic profile   
   Monica Levy Andersen
      2013   -   NCT01921374   Brazil;
Metformin   
   University Hospital, Basel, Switzerland
      2012   Phase 1   NCT02516085   -
Metformin and Metformin & L-Citrulline   
   University Hospital, Basel, Switzerland
      2013   Phase 2   NCT02018731   Switzerland;
Methylphenidate   
   Laval University
      2008   Phase 2/Phase 3   NCT01421992   Canada;
MetoHEXAL® Succ ® 23,75 mg Retardtabletten   
   Friedrich- Alexander- Universität Erlangen Nürnberg
      -   -   EUCTR2009-009871-36-DE   Germany;
MetoHEXAL® Succ ® 47,5 mg Retardtabletten   
   Friedrich- Alexander- Universität Erlangen Nürnberg
      -   -   EUCTR2009-009871-36-DE   Germany;
MetoHEXAL® Succ ® 95 mg Retardtabletten   
   Friedrich- Alexander- Universität Erlangen Nürnberg
      -   -   EUCTR2009-009871-36-DE   Germany;
Metoprolol   
   West China Second University Hospital, Sichuan University
      2020   Phase 4   ChiCTR2000032525   China;
Mexiletine   
   Lupin Ltd.
      2021   Phase 3   NCT04700046   -
      2021   Phase 3   NCT04624750   France;
      2020   -   NCT04616807   France;Germany;United Kingdom;
   University of Rochester
      2011   Phase 2   NCT01406873   United States;
Monocytes and megacaryocytes culture and RNA extraction   
   Assistance Publique - Hôpitaux de Paris
      2018   -   NCT03424460   France;
Moxifloxacin Hydrochloride   
   Italfarmaco
      2021   Phase 1   NCT04821063   Canada;
Myoblast autologous graft   
   University Hospital, Caen
      2019   Phase 2/Phase 3   NCT02878694   France;
Myoblast transplantation   
   CHU de Quebec-Universite Laval
      2014   Phase 1/Phase 2   NCT02196467   Canada;
Myoblastes autologues   
   CHU CAEN
      2019   Phase 2   EUCTR2015-001192-48-FR   France;
N(4,5Bis methanesulfonyl2methylbenzoyl) guanidine hydrochloride monohydrate   
   EspeRare
      2015   Phase 1   EUCTR2015-002530-50-ES   France;Italy;Spain;Switzerland;United Kingdom;
N-(4,5-Bis methanesulfonyl-2-methyl-benzoyl)guanidine hydrochloride monohydrate   
   EspeRare
      2015   Phase 1   EUCTR2015-002530-50-GB   France;Italy;Spain;Switzerland;United Kingdom;
      2015   Phase 1   EUCTR2015-002530-50-FR   France;Italy;Spain;Switzerland;United Kingdom;
NPC-14   
   Kobe University
      2013   Phase 2   NCT01918384   Japan;
   Yasuhiro Takeshima, MD, PhDHyogo College of Medicine Hospital, department of pediatrics
      2013   Phase 2   JPRN-JMA-IIA00134   Japan;
NS-065/NCNP-01   
   NS Pharma, Inc
      2021   Phase 3   EUCTR2021-000122-10-IT   Australia;Canada;Chile;China;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-003653-30-IT   China;Italy;Russian Federation;Spain;Turkey;United States;
      2020   Phase 3   EUCTR2019-002076-13-IT   Australia;Belgium;Brazil;Canada;Chile;France;Greece;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
   NS Pharma, Inc.
      2021   Phase 3   EUCTR2021-000122-10-NL   Australia;Canada;Chile;China;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000122-10-GR   Australia;Canada;Chile;China;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000122-10-ES   Australia;Canada;Chile;China;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-002076-13-NO   Australia;Canada;Chile;China;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-003653-30-ES   China;Italy;Russian Federation;Spain;Turkey;United States;
      2020   Phase 3   EUCTR2019-002076-13-NL   Australia;Canada;Chile;China;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002076-13-GR   Australia;Canada;Chile;China;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002076-13-GB   Australia;Belgium;Brazil;Canada;Chile;France;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-002076-13-ES   Australia;Belgium;Brazil;Canada;Chile;France;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 2   NCT03167255   Canada;United States;
      2016   Phase 2   NCT02740972   Canada;United States;
      -   Phase 3   EUCTR2019-002076-13-SE   Australia;Belgium;Brazil;Canada;Chile;France;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
   National Center of Neurology and Psychiatry, Japan
      2013   Phase 1   NCT02081625   Japan;
NS-089/NCNP-02   
   National Center of Neurology and Psychiatry, Japan
      2019   Phase 1/Phase 2   NCT04129294   Japan;
   Nippon Shinyaku Co., Ltd.
      2021   Phase 2   NCT05135663   Japan;
Nanosuspension)   
   Summit (Oxford) Limited
      2015   Phase 1   EUCTR2015-001967-38-GB   United Kingdom;
Nebivolol   
   Assistance Publique - Hôpitaux de Paris
      2012   Phase 3   NCT01648634   France;
Needle biopsy of the vastus lateralis muscle   
   University Hospital, Montpellier
      2010   -   NCT01596803   France;
Nébivolol   
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      -   Phase 3   EUCTR2010-020047-12-FR   France;
Oligomero morfolino fosforodiamidato per skipping dell’esone 45   
   SAREPTA THERAPEUTICS, INC.
      2017   Phase 3   EUCTR2015-002069-52-IT   Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
Oligomero morfolino fosforodiamidato per skipping dell’esone 53   
   SAREPTA THERAPEUTICS, INC.
      2017   Phase 3   EUCTR2015-002069-52-IT   Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
Omigapil   
   Santhera Pharmaceuticals
      2014   Phase 1   NCT01805024   United States;
Oxatomide (tinset)   
   Cooperative International Neuromuscular Research Group
      2002   Phase 2   NCT00033813   United States;
P-188 NF   
   Phrixus Pharmaceuticals, Inc.
      2018   Phase 2   NCT03558958   United States;
PB1046 Injection   
   PhaseBio Pharmaceuticals Inc.
      2016   Phase 2   NCT02808585   United States;
PF-06252616   
   Pfizer
      2016   Phase 2   NCT02907619   Canada;Italy;Japan;United Kingdom;United States;
      2014   Phase 2   NCT02310763   Australia;Bulgaria;Canada;Italy;Japan;Poland;United Kingdom;United States;
   Pfizer Inc.
      2016   Phase 2   EUCTR2016-001615-21-GB   Australia;Bulgaria;Canada;Italy;Japan;Poland;United Kingdom;United States;
   Pfizer Inc. 235 East 42nd Street, New York, NY 10017
      2018   Phase 2   EUCTR2016-001615-21-BG   Australia;Bulgaria;Canada;Italy;Japan;Poland;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-001615-21-IT   Australia;Bulgaria;Canada;Italy;Japan;Poland;United Kingdom;United States;
      2016   Phase 2   EUCTR2014-002072-92-PL   Australia;Bulgaria;Canada;Italy;Japan;Poland;United Kingdom;United States;
      2016   Phase 2   EUCTR2014-002072-92-BG   Australia;Bulgaria;Canada;Italy;Japan;Poland;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-002072-92-IT   Bulgaria;Canada;Italy;Japan;Poland;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-002072-92-GB   Australia;Bulgaria;Canada;Italy;Japan;Poland;United Kingdom;United States;
PF-06939926   
   PFIZER INC
      2020   Phase 3   EUCTR2019-002921-31-IT   Belgium;Canada;China;France;Germany;Israel;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
   Pfizer Inc.
      2021   Phase 3   EUCTR2019-002921-31-FR   Belgium;Canada;China;France;Germany;Israel;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-002921-31-BE   Belgium;Canada;China;France;Germany;Israel;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002921-31-GB   Belgium;Canada;China;France;Germany;Israel;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
PFT   
   University of Florida
      2013   -   NCT02195999   United States;
PRD2175434   
   The Newcastle upon Tyne NHS Hospitals Foundation Trust
      2015   Phase 3   EUCTR2015-003195-68-GB   United Kingdom;
PRO044   
   BioMarin Nederland B.V.
      2014   Phase 2   EUCTR2013-003605-26-SE   Belgium;Netherlands;Sweden;
   PROSENSA THERAPEUTICS BV
      2010   -   EUCTR2009-013762-63-IT   Belgium;Italy;Netherlands;Sweden;
   Prosensa Therapeutics B.V
      2010   -   EUCTR2009-013762-63-SE   Belgium;Italy;Netherlands;Sweden;
      2010   -   EUCTR2009-013762-63-NL   Belgium;Italy;Netherlands;Sweden;
      2009   Phase 1;Phase 2   EUCTR2009-013762-63-BE   Belgium;Italy;Netherlands;Sweden;
   Prosensa Therapeutics B.V.
      2015   Phase 2   EUCTR2013-003605-26-NL   Belgium;Netherlands;Sweden;
      2015   Phase 2   EUCTR2013-003605-26-BE   Belgium;Netherlands;Sweden;
      2014   Phase 2   EUCTR2013-003605-26-IT   Belgium;Italy;Netherlands;Sweden;
PRO044 IV   
   BioMarin Pharmaceutical
      2014   Phase 2   NCT02329769   Belgium;Italy;Netherlands;Sweden;
      2009   Phase 1/Phase 2   NCT01037309   Belgium;Italy;Netherlands;Sweden;
PRO044 SC   
   BioMarin Pharmaceutical
      2014   Phase 2   NCT02329769   Belgium;Italy;Netherlands;Sweden;
      2009   Phase 1/Phase 2   NCT01037309   Belgium;Italy;Netherlands;Sweden;
PRO045   
   BioMarin Nederland B.V.
      2012   Phase 1;Phase 2   EUCTR2011-005040-10-BE   Belgium;Italy;United Kingdom;
   Prosensa Therapeutics BV
      2013   Phase 1;Phase 2   EUCTR2011-005040-10-IT   Belgium;Italy;United Kingdom;
      -   Phase 1;Phase 2   EUCTR2011-005040-10-FR   Belgium;France;Italy;United Kingdom;
PRO045, 0.15 mg/kg/week   
   BioMarin Pharmaceutical
      2013   Phase 1/Phase 2   NCT01826474   Belgium;France;Italy;Netherlands;United Kingdom;
PRO045, 1.0 mg/kg/week   
   BioMarin Pharmaceutical
      2013   Phase 1/Phase 2   NCT01826474   Belgium;France;Italy;Netherlands;United Kingdom;
PRO045, 3.0 mg/kg/week   
   BioMarin Pharmaceutical
      2013   Phase 1/Phase 2   NCT01826474   Belgium;France;Italy;Netherlands;United Kingdom;
PRO045, 6.0 mg/kg/week   
   BioMarin Pharmaceutical
      2013   Phase 1/Phase 2   NCT01826474   Belgium;France;Italy;Netherlands;United Kingdom;
PRO045, 9.0 mg/kg/week   
   BioMarin Pharmaceutical
      2013   Phase 1/Phase 2   NCT01826474   Belgium;France;Italy;Netherlands;United Kingdom;
PRO045, selected dose   
   BioMarin Pharmaceutical
      2013   Phase 1/Phase 2   NCT01826474   Belgium;France;Italy;Netherlands;United Kingdom;
PRO051   
   Prosensa Holding B.V.
      2008   -   EUCTR2007-004819-54-NL   Belgium;Netherlands;Sweden;
   Prosensa Therapeutics BV
      2008   Phase 1;Phase 2   EUCTR2007-004819-54-SE   Belgium;Netherlands;Sweden;
      2008   Phase 1;Phase 2   EUCTR2007-004819-54-BE   Belgium;Netherlands;Sweden;
PRO053   
   Prosensa Therapeutics BV
      2013   Phase 1;Phase 2   EUCTR2011-005042-35-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Turkey;United Kingdom;United States;
      2013   Phase 1;Phase 2   EUCTR2011-005042-35-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Turkey;United Kingdom;United States;
      -   Phase 1;Phase 2   EUCTR2011-005042-35-FR   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Turkey;United Kingdom;United States;
PROVIGIL - 100 MG COMPRESSE 30 COMPRESSE   
   FONDAZIONE SERENA ONLUS
      2016   Phase 3   EUCTR2016-000601-36-IT   Italy;
PS188   
   BIOMARIN PHARMACEUTICAL INC.
      -   Phase 2   EUCTR2015-003681-87-IT   Belgium;Italy;Netherlands;Sweden;United States;
PS188 (company code)   
   BioMarin Nederland B.V.
      2014   Phase 2   EUCTR2013-003605-26-SE   Belgium;Netherlands;Sweden;
   BioMarin Pharmaceutical Inc.
      2016   Phase 2   EUCTR2015-003681-87-BE   Belgium;Italy;Netherlands;Sweden;United States;
   Prosensa Therapeutics B.V.
      2015   Phase 2   EUCTR2013-003605-26-NL   Belgium;Netherlands;Sweden;
      2015   Phase 2   EUCTR2013-003605-26-BE   Belgium;Netherlands;Sweden;
      2014   Phase 2   EUCTR2013-003605-26-IT   Belgium;Italy;Netherlands;Sweden;
PS220   
   BioMarin Nederland B.V.
      2012   Phase 1;Phase 2   EUCTR2011-005040-10-BE   Belgium;Italy;United Kingdom;
   BioMarin Pharmaceutical Inc.
      2013   Phase 1;Phase 2   EUCTR2011-005040-10-GB   Belgium;France;Italy;United Kingdom;
   Prosensa Therapeutics BV
      2013   Phase 1;Phase 2   EUCTR2011-005040-10-IT   Belgium;Italy;United Kingdom;
      -   Phase 1;Phase 2   EUCTR2011-005040-10-FR   Belgium;France;Italy;United Kingdom;
PS524   
   BioMarin Nederland B.V.
      2013   Phase 1;Phase 2   EUCTR2011-005042-35-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Turkey;United Kingdom;United States;
   BioMarin Pharmaceutical Inc.
      2013   Phase 1;Phase 2   EUCTR2011-005042-35-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Turkey;United Kingdom;United States;
   Prosensa Therapeutics BV
      2013   Phase 1;Phase 2   EUCTR2011-005042-35-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Turkey;United Kingdom;United States;
      2013   Phase 1;Phase 2   EUCTR2011-005042-35-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Turkey;United Kingdom;United States;
      -   Phase 1;Phase 2   EUCTR2011-005042-35-FR   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Turkey;United Kingdom;United States;
PTC0161480, PTC124 Compound 1a, RPS2505, PTC-C124, 291844   
   PTC Therapeutics Inc
      2010   -   EUCTR2009-013169-24-GB   United Kingdom;
   PTC Therapeutics, Inc.
      2009   Phase 2   EUCTR2008-007648-32-FR   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom;
      2009   Phase 2   EUCTR2008-007648-32-ES   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom;
      2009   Phase 2   EUCTR2007-005478-29-GB   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-007648-32-SE   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-007648-32-GB   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-007648-32-DE   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-007648-32-BE   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom;
      2008   Phase 2   EUCTR2007-005478-29-FR   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom;
      2008   Phase 2   EUCTR2007-005478-29-ES   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-005478-29-SE   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-005478-29-DE   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-005478-29-BE   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom;
PTC124   
   PTC THERAPEUTICS, INC.
      2012   Phase 3   EUCTR2011-004853-18-IT   Australia;Belgium;Canada;Germany;Israel;Italy;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-007648-32-IT   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-005478-29-IT   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom;
   PTC Therapeutics
      2005   Phase 2   NCT00264888   United States;
   PTC Therapeutics, Inc
      2014   -   EUCTR2012-004527-20-PL   Australia;Belgium;Brazil;Canada;Chile;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-004527-20-SE   Australia;Belgium;Brazil;Canada;Chile;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-004527-20-GB   Australia;Belgium;Brazil;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-004527-20-DE   Australia;Belgium;Brazil;Canada;Chile;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-004527-20-CZ   Australia;Belgium;Brazil;Canada;Chile;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-004527-20-BE   Australia;Belgium;Brazil;Canada;Chile;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-004527-20-IT   Australia;Belgium;Brazil;Canada;Chile;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-004527-20-ES   Australia;Belgium;Brazil;Canada;Chile;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-004853-18-SE   Australia;Belgium;Canada;Germany;Israel;Italy;Spain;Sweden;United Kingdom;
      2012   Phase 3   EUCTR2011-004853-18-FR   Australia;Belgium;Canada;France;Germany;Israel;Italy;Spain;Sweden;United Kingdom;
      2012   Phase 3   EUCTR2011-004853-18-ES   Australia;Belgium;Canada;Germany;Israel;Italy;Spain;Sweden;United Kingdom;
      2012   Phase 3   EUCTR2011-004853-18-BE   Australia;Belgium;Canada;Germany;Israel;Italy;Spain;Sweden;United Kingdom;
      -   Phase 3   EUCTR2012-004527-20-FR   Australia;Belgium;Brazil;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   PTC Therapeutics, Inc.
      2018   Phase 3   EUCTR2017-001223-49-BG   Argentina;Australia;Brazil;Bulgaria;Canada;China;Hong Kong;India;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;Taiwan;Thailand;Turkey;United States;
      2016   Phase 3   EUCTR2013-005489-20-FR   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2015   Phase 3   EUCTR2013-005489-20-CZ   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2015   Phase 3   EUCTR2013-005489-20-BG   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005489-20-SE   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005489-20-IT   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005489-20-GB   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005489-20-ES   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005489-20-DE   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005489-20-BE   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-004853-18-GB   Australia;Belgium;Canada;France;Germany;Israel;Italy;Spain;Sweden;United Kingdom;
      2012   Phase 3   EUCTR2011-004853-18-DE   Australia;Belgium;Canada;Germany;Israel;Italy;Spain;Sweden;United Kingdom;
      -   Phase 3   EUCTR2017-001223-49-PL   Argentina;Australia;Brazil;Bulgaria;Canada;China;Hong Kong;India;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;Taiwan;Thailand;Turkey;United States;
      -   Phase 2   EUCTR2020-000980-21-Outside-EU/EEA   United States;
Pamrevlumab   
   FibroGen
      2020   Phase 3   NCT04632940   Australia;Austria;Belgium;Canada;China;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
      2020   Phase 3   NCT04371666   Australia;Austria;Belgium;Canada;China;Czechia;France;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
Pamrevlumab (FG-3019)   
   FibroGen
      2015   Phase 2   NCT02606136   United States;
Pending   
   Acceleron Pharma Inc.
      2019   Phase 2   EUCTR2019-000305-79-ES   Canada;Spain;United States;
      2018   Phase 2   EUCTR2016-003257-15-ES   Canada;Spain;United States;
   Summit (Oxford) Limited
      2016   Phase 2   EUCTR2015-004333-27-GB   United Kingdom;United States;
Pentoxifylline   
   Cooperative International Neuromuscular Research Group
      2005   Phase 1/Phase 2   NCT00243789   Argentina;Australia;Canada;Israel;Italy;United States;
      2002   Phase 1/Phase 2   NCT00102453   United States;
Peptide-conjugated phosphorodiamidate morpholino oligomer for exon 51 skipping   
   Sarepta Therapeutics, Inc.
      2021   Phase 2   EUCTR2019-000601-77-DE   Belgium;Canada;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-000601-77-NL   Belgium;Canada;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-000601-77-ES   Belgium;Canada;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000601-77-IE   Belgium;Canada;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000601-77-GB   Belgium;Canada;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      -   Phase 2   EUCTR2019-000601-77-BE   Belgium;Canada;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
Perindopril   
   West China Second University Hospital, Sichuan University
      2020   Phase 4   ChiCTR2000032525   China;
Perindopril 2mg Tablets   
   Newcastle upon Tyne Hospitals NHS Foundation Trust
      2009   Phase 3   EUCTR2007-005932-10-GB   United Kingdom;
Phosphorodiamidate Morpholino Oligomer   
   Imperial College, London
      2007   Phase 1;Phase 2   EUCTR2006-003833-33-GB   United Kingdom;
Phosphorodiamidate morpholino oligomer for exon 45 skipping   
   Sarepta Therapeutics, Inc.
      2020   Phase 3   EUCTR2017-004625-32-SE   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2017-004625-32-BG   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2015-002069-52-NO   Australia;Belgium;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2015-002069-52-IE   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004625-32-FR   Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2015-002069-52-GR   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2015-002069-52-DK   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004625-32-GB   Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004625-32-ES   Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004625-32-BE   Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2015-002069-52-PL   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2015-002069-52-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-002069-52-SE   Australia;Belgium;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-002069-52-GB   Australia;Belgium;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-002069-52-ES   Canada;Germany;Israel;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-002069-52-DE   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-002069-52-CZ   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-002069-52-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2017-004625-32-PL   Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2017-004625-32-DE   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2017-004625-32-CZ   Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2015-002069-52-FR   Belgium;Canada;Czech Republic;France;Germany;Spain;United Kingdom;United States;
Phosphorodiamidate morpholino oligomer for exon 53 skipping   
   Sarepta Therapeutics, Inc.
      2020   Phase 3   EUCTR2017-004625-32-SE   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2017-004625-32-BG   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2015-002069-52-NO   Australia;Belgium;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2015-002069-52-IE   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004625-32-FR   Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2015-002069-52-GR   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2015-002069-52-DK   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004625-32-GB   Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004625-32-ES   Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004625-32-BE   Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2015-002069-52-PL   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2015-002069-52-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-002069-52-SE   Australia;Belgium;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-002069-52-GB   Australia;Belgium;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-002069-52-ES   Canada;Germany;Israel;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-002069-52-DE   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-002069-52-CZ   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-002069-52-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2016   Phase 1;Phase 2   EUCTR2014-002008-25-FR   France;Italy;United Kingdom;
      2014   Phase 1;Phase 2   EUCTR2014-002008-25-IT   France;Italy;United Kingdom;
      2014   Phase 1;Phase 2   EUCTR2014-002008-25-GB   France;Italy;United Kingdom;United States;
      -   Phase 3   EUCTR2017-004625-32-PL   Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2017-004625-32-DE   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2017-004625-32-CZ   Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2015-002069-52-FR   Belgium;Canada;Czech Republic;France;Germany;Spain;United Kingdom;United States;
Pitolisant Oral Tablet   
   Harmony Biosciences, LLC
      2021   Phase 2   NCT04886518   United States;
Powder for Oral Suspension)   
   Summit (Oxford) Limited
      2015   Phase 1   EUCTR2015-001967-38-GB   United Kingdom;
Prednisolone   
   Kevin Flanigan
      2018   Phase 1   NCT03777319   United States;
   Washington University School of Medicine
      2014   Phase 2   NCT02167217   United States;
Prednison   
   Universitätsklinik Freiburg
      2005   Phase 2;Phase 3   EUCTR2005-000663-26-AT   Austria;
Prednisone   
   Ann & Robert H Lurie Children's Hospital of Chicago
      2014   Phase 2   NCT02036463   United States;
   Cooperative International Neuromuscular Research Group
      2007   Phase 3   NCT00308113   Australia;Puerto Rico;United States;
      2004   Phase 3   NCT00110669   India;United States;
   National Center for Research Resources (NCRR)
      1995   Phase 3   NCT00004646   -
   Northwestern University
      2019   Phase 2   NCT04054375   United States;
   ReveraGen BioPharma, Inc.
      2018   Phase 2   NCT03439670   Australia;Belgium;Canada;Czechia;Germany;Greece;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
   University of Rochester
      2013   Phase 3   NCT01603407   Canada;Germany;Italy;United Kingdom;United States;
   University of Sao Paulo
      2013   -   NCT04740554   -
Prednisone 5 mg tablets   
   University of Rochester
      2012   -   EUCTR2010-023744-33-GB   Canada;Germany;Italy;United Kingdom;United States;
Prednisone plus exercise   
   University of Florida
      2020   Phase 2   NCT04322357   United States;
Prednisone with daily edasalonexent   
   University of Florida
      2020   Phase 2   NCT04322357   United States;
Protein-carbohydrate supplementation   
   Grete Andersen, MD
      2012   -   NCT01618331   Denmark;
RAAV1.CMV.huFollistatin344   
   Nationwide Children's Hospital
      2012   Phase 1   NCT01519349   United States;
RAAV1.CMV.huFollistin344   
   Jerry R. Mendell
      2015   Phase 1/Phase 2   NCT02354781   United States;
RAAV2.5-CMV-minidystrophin (d3990)   
   Nationwide Children's Hospital
      2006   Phase 1   NCT00428935   United States;
RAAV8-hMD1   
   Genethon
      2020   Phase 1;Phase 2;Phase 3   EUCTR2020-002093-27-FR   France;Israel;United Kingdom;United States;
RAAV9-CK8-h-µD5   
   Solid Biosciences Inc.
      2019   Phase 1;Phase 2   EUCTR2017-002213-60-GB   United Kingdom;United States;
RAAV9-hFKRPco_miR-208a   
   Atamyo Therapeutics
      2022   Phase 1;Phase 2   EUCTR2021-004276-33-DK   Canada;Denmark;France;Germany;Norway;Sweden;United Kingdom;United States;
RAAVrh74.MCK.GALGT2   
   Kevin Flanigan
      2017   Phase 1/Phase 2   NCT03333590   United States;
      2016   Phase 1/Phase 2   NCT02704325   United States;
RAAVrh74.MCK.micro-Dystrophin   
   Jerry R. Mendell
      2015   Phase 1   NCT02376816   United States;
RAXONE - 150 MG- COMPRESSE RIVESTITE CON FILM- USO ORALE- FLACONE (HDPE)- 180 COMPRESSE   
   SANTHERA PHARMACEUTICALS
      2016   Phase 3   EUCTR2016-000602-10-IT   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
RO7239361   
   Hoffmann-La Roche
      2017   Phase 2/Phase 3   NCT03039686   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
      2015   Phase 1/Phase 2   NCT02515669   Canada;United States;
RO7239361 (BMS-986089)   
   F. Hoffmann-La Roche Ltd
      2017   Phase 3   EUCTR2016-001654-18-BE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
RO7239361 Injections, 15 mg/Syringe (21.4 mg/mL)   
   F. Hoffmann-La Roche Ltd
      2017   Phase 3   EUCTR2016-001654-18-SE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001654-18-NL   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001654-18-GB   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001654-18-DE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
RO7239361 Injections, 35 mg/Syringe (50 mg/mL)   
   F. Hoffmann-La Roche Ltd
      2017   Phase 3   EUCTR2016-001654-18-SE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001654-18-NL   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001654-18-GB   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001654-18-DE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
RO7239361 Injections, 50 mg/Syringe (71.4 mg/mL)   
   F. Hoffmann-La Roche Ltd
      2017   Phase 3   EUCTR2016-001654-18-SE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001654-18-NL   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001654-18-GB   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001654-18-DE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
RO7239361 Injections, 7.5 mg/Syringe (10.7 mg/mL)   
   F. Hoffmann-La Roche Ltd
      2017   Phase 3   EUCTR2016-001654-18-SE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001654-18-NL   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001654-18-GB   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001654-18-DE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
Ramipril   
   Catholic University, Italy
      2008   Phase 4   NCT00819845   Italy;
   POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
      2008   -   EUCTR2008-007236-18-IT   Italy;
Ranolazine   
   Ohio State University
      2014   Phase 1   NCT02251457   United States;
Raxone   
   SANTHERA PHARMACEUTICALS
      2018   Phase 3   EUCTR2017-004279-30-IT   Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
   Santhera Pharmaceuticals (Switzerland) Limited
      2020   Phase 3   EUCTR2017-004279-30-NL   Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2020   Phase 3   EUCTR2016-000602-10-BG   Austria;Belgium;Bulgaria;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004279-30-AT   Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004279-30-GB   Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004279-30-ES   Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004279-30-BE   Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-000602-10-HU   Austria;Belgium;Bulgaria;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000602-10-NL   Austria;Belgium;Bulgaria;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000602-10-GB   Austria;Belgium;Bulgaria;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000602-10-FR   Austria;Belgium;Bulgaria;France;Germany;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000602-10-ES   Austria;Belgium;Bulgaria;France;Germany;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000602-10-DE   Austria;Belgium;Bulgaria;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000602-10-BE   Austria;Belgium;Bulgaria;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000602-10-AT   Austria;Belgium;Bulgaria;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2017-004279-30-SE   Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2017-004279-30-FR   Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2017-004279-30-DE   Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2016-000602-10-SE   Austria;Belgium;Bulgaria;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2016-000602-10-IE   Austria;Belgium;Bulgaria;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
Recombinant human anti-GDF-8 antibody   
   Wyeth Research Division of Wyeth Pharmaceuticals Inc.
      2005   Phase 2   EUCTR2004-000622-67-GB   United Kingdom;
Regimen Selection Phase Group 1 (COMPLETED)   
   BioMarin Pharmaceutical
      2013   Phase 1/Phase 2   NCT01957059   Belgium;France;Italy;Netherlands;United Kingdom;
Regimen Selection Phase Group 2   
   BioMarin Pharmaceutical
      2013   Phase 1/Phase 2   NCT01957059   Belgium;France;Italy;Netherlands;United Kingdom;
Regimen Selection Phase Group 3   
   BioMarin Pharmaceutical
      2013   Phase 1/Phase 2   NCT01957059   Belgium;France;Italy;Netherlands;United Kingdom;
Resveratrol   
   Sapporo Medical University
      2014   -   JPRN-UMIN000014836   Japan;
Revatio   
   Rigshospitalet
      2011   -   EUCTR2010-024659-10-DK   Denmark;
RhIGF-I/rhIGFBP-3   
   Insmed Incorporated
      2007   Phase 2   NCT00577577   United States;
Rimeporide   
   ESPERARE FOUNDATION
      2017   Phase 1   EUCTR2015-002530-50-IT   France;Italy;Spain;United Kingdom;
   EspeRare
      2015   Phase 1   EUCTR2015-002530-50-GB   France;Italy;Spain;Switzerland;United Kingdom;
      2015   Phase 1   EUCTR2015-002530-50-FR   France;Italy;Spain;Switzerland;United Kingdom;
      2015   Phase 1   EUCTR2015-002530-50-ES   France;Italy;Spain;Switzerland;United Kingdom;
   EspeRare Foundation
      2016   Phase 1   NCT02710591   France;Italy;Spain;United Kingdom;
Risedronate sodium   
   The Central Remedial Clinic and The Children's University Hospital
      2010   -   EUCTR2009-017649-67-IE   Ireland;
SGT-001   
   Solid Biosciences Inc.
      2019   Phase 1;Phase 2   EUCTR2017-002213-60-GB   United Kingdom;United States;
SMT C1100   
   Summit (Oxford) Limited
      2016   Phase 2   EUCTR2015-004333-27-GB   United Kingdom;United States;
      2014   Phase 1   EUCTR2014-003100-78-GB   United Kingdom;
   Summit Corporation Plc.
      2013   Phase 1   NCT02056808   United Kingdom;
   Summit Corporation plc
      2013   Phase 1   EUCTR2013-002115-99-GB   United Kingdom;
   Summit Therapeutics
      2015   Phase 1   NCT02383511   United Kingdom;
SMT C1100 (F5)   
   Summit (Oxford) Limited
      2015   Phase 1   EUCTR2015-001967-38-GB   United Kingdom;
SMT C1100 (F6)   
   Summit (Oxford) Limited
      2015   Phase 1   EUCTR2015-001967-38-GB   United Kingdom;
SNT-MC17   
   Santhera Pharmaceuticals (Switzerland) Limited
      2012   -   EUCTR2009-012037-30-ES   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United States;
      2010   -   EUCTR2009-012037-30-SE   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United States;
      2010   -   EUCTR2009-012037-30-NL   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United States;
      2010   -   EUCTR2009-012037-30-FR   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;
      2010   -   EUCTR2009-012037-30-AT   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United States;
      2009   Phase 3   EUCTR2009-012037-30-BE   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United States;
      2009   -   EUCTR2009-012037-30-DE   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United States;
   Santhera Pharmaceuticals (Switzerland) Ltd
      2008   -   EUCTR2007-007752-34-BE   Belgium;
SRP-4045   
   SAREPTA THERAPEUTICS, INC.
      2017   Phase 3   EUCTR2015-002069-52-IT   Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
   Sarepta Therapeutics, Inc.
      2020   Phase 3   EUCTR2017-004625-32-SE   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2017-004625-32-BG   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2015-002069-52-NO   Australia;Belgium;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2015-002069-52-IE   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004625-32-FR   Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2015-002069-52-GR   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2015-002069-52-DK   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004625-32-GB   Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004625-32-ES   Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004625-32-BE   Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2015-002069-52-PL   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2015-002069-52-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-002069-52-SE   Australia;Belgium;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-002069-52-GB   Australia;Belgium;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-002069-52-ES   Canada;Germany;Israel;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-002069-52-DE   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-002069-52-CZ   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-002069-52-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2016   Phase 3   NCT02500381   Australia;Belgium;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Poland;Russian Federation;Serbia;Spain;Sweden;United Kingdom;United States;
      2015   Phase 1   NCT02530905   United States;
      -   Phase 3   EUCTR2017-004625-32-PL   Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2017-004625-32-DE   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2017-004625-32-CZ   Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2015-002069-52-FR   Belgium;Canada;Czech Republic;France;Germany;Spain;United Kingdom;United States;
SRP-4053   
   SAREPTA THERAPEUTICS, INC.
      2017   Phase 3   EUCTR2015-002069-52-IT   Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
   Sarepta Therapeutics, Inc.
      2020   Phase 3   EUCTR2017-004625-32-SE   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2017-004625-32-BG   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2015-002069-52-NO   Australia;Belgium;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2015-002069-52-IE   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004625-32-FR   Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2015-002069-52-GR   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2015-002069-52-DK   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004625-32-GB   Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004625-32-ES   Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004625-32-BE   Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2015-002069-52-PL   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2015-002069-52-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-002069-52-SE   Australia;Belgium;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-002069-52-GB   Australia;Belgium;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-002069-52-ES   Canada;Germany;Israel;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-002069-52-DE   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-002069-52-CZ   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-002069-52-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2016   Phase 3   NCT02500381   Australia;Belgium;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Poland;Russian Federation;Serbia;Spain;Sweden;United Kingdom;United States;
      2016   Phase 1;Phase 2   EUCTR2014-002008-25-FR   France;Italy;United Kingdom;
      2015   Phase 1/Phase 2   NCT02310906   France;Italy;United Kingdom;United States;
      2014   Phase 1;Phase 2   EUCTR2014-002008-25-IT   France;Italy;United Kingdom;
      2014   Phase 1;Phase 2   EUCTR2014-002008-25-GB   France;Italy;United Kingdom;United States;
      -   Phase 3   EUCTR2017-004625-32-PL   Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2017-004625-32-DE   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2017-004625-32-CZ   Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2015-002069-52-FR   Belgium;Canada;Czech Republic;France;Germany;Spain;United Kingdom;United States;
SRP-5051   
   Sarepta Therapeutics, Inc.
      2021   Phase 2   EUCTR2019-000601-77-DE   Belgium;Canada;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-000601-77-NL   Belgium;Canada;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-000601-77-ES   Belgium;Canada;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 2   NCT04004065   Belgium;Canada;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000601-77-IE   Belgium;Canada;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000601-77-GB   Belgium;Canada;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2018   Phase 1/Phase 2   NCT03675126   Canada;United States;
      2018   Phase 1   NCT03375255   Canada;United States;
      -   Phase 2   EUCTR2019-000601-77-BE   Belgium;Canada;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
SRP-9001   
   Sarepta Therapeutics, Inc.
      2022   Phase 3   EUCTR2019-003374-91-ES   Belgium;France;Germany;Hong Kong;Italy;Japan;Spain;Taiwan;United Kingdom;United States;
Saline injection   
   CHU de Quebec-Universite Laval
      2014   Phase 1/Phase 2   NCT02196467   Canada;
Sandimmun Optoral   
   Universitätsklinik Freiburg
      2005   Phase 2;Phase 3   EUCTR2005-000663-26-AT   Austria;
ScAAV9.U7.ACCA   
   Megan Waldrop
      2020   Phase 1/Phase 2   NCT04240314   United States;
ScAAVrh74.tMCK.hSGCA   
   Jerry R. Mendell
      2015   Phase 1/Phase 2   NCT01976091   United States;
Sildenafil   
   Cedars-Sinai Medical Center
      2011   Early Phase 1   NCT01359670   United States;
   Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
      2010   Phase 2   NCT01168908   United States;
   Rigshospitalet
      2011   -   EUCTR2010-024659-10-DK   Denmark;
   Rigshospitalet, Denmark
      2011   Phase 2   NCT01350154   Denmark;
Sleep parameters   
   Monica Levy Andersen
      2013   -   NCT01921374   Brazil;
Sodium Nitrate - double dose   
   Cedars-Sinai Medical Center
      2013   Phase 2/Phase 3   NCT02147639   United States;
Sodium nitrate   
   Cedars-Sinai Medical Center
      2013   Phase 1   NCT02847975   United States;
SomatoKine/IPLEX   
   University of Rochester
      2005   Phase 1/Phase 2   NCT00233519   United States;
Somatropin   
   University of Rochester
      2017   Phase 1   NCT03123913   United States;
Spironolactone   
   Kevin Flanigan
      2018   Phase 1   NCT03777319   United States;
   Ohio State University
      2015   Phase 3   NCT02354352   United States;
Stem Cell   
   Chaitanya Hospital, Pune
      2014   Phase 1/Phase 2   NCT01834066   India;
   Neurogen Brain and Spine Institute
      2010   Phase 1   NCT02245711   India;
      2009   Phase 1   NCT02241928   India;
      2009   Phase 1   NCT02241434   India;
Stem Cells   
   Stem Cells Arabia
      2015   Phase 1/Phase 2   NCT03067831   Jordan;
Sunphenon EGCG   
   Charite Universitätsmedizin Berlin
      2010   Phase 2   EUCTR2009-016482-28-DE   Germany;
Sustanon (testosterone)   
   Newcastle-upon-Tyne Hospitals NHS Trust
      2015   -   NCT02571205   United Kingdom;
Sustanon 250   
   The Newcastle upon Tyne NHS Hospitals Foundation Trust
      2015   Phase 3   EUCTR2015-003195-68-GB   United Kingdom;
Suvodirsen   
   Wave Life Sciences UK Limited
      2019   Phase 2;Phase 3   EUCTR2018-004009-22-SE   Australia;Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-004009-22-IT   Australia;Belgium;Canada;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-004009-22-GB   Australia;Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-004009-22-CZ   Australia;Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-004009-22-BE   Australia;Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2018-004009-22-PL   Australia;Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2018-004009-22-NL   Australia;Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2018-004009-22-FR   Australia;Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2018-004009-22-DE   Australia;Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States;
Synacthen Ampoules 250 mcg   
   MALLINCKRODT ARD INC.
      2018   Phase 2   EUCTR2017-004139-35-IT   Bulgaria;Canada;Costa Rica;India;Ireland;Israel;Italy;Mexico;Poland;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States;
Synacthen Ampoules 250 microgrammi   
   MALLINCKRODT ARD INC.
      2018   Phase 2   EUCTR2017-004139-35-IT   Bulgaria;Canada;Costa Rica;India;Ireland;Israel;Italy;Mexico;Poland;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States;
TAMOX   
   University of Basel Children's Hospital, Division of Neuropediatrics
      2019   Phase 3   EUCTR2017-004554-42-ES   Belgium;France;Germany;Netherlands;Spain;Switzerland;Turkey;United Kingdom;
TAMOXIFEN CITRATE   
   University of Basel Children's Hospital, Division of Neuropediatrics
      2020   Phase 3   EUCTR2017-004554-42-FR   Belgium;France;Germany;Netherlands;Spain;Switzerland;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004554-42-NL   Belgium;France;Germany;Netherlands;Spain;Switzerland;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004554-42-GB   Belgium;France;Germany;Netherlands;Spain;Switzerland;United Kingdom;
      2019   Phase 3   EUCTR2017-004554-42-ES   Belgium;France;Germany;Netherlands;Spain;Switzerland;Turkey;United Kingdom;
      -   Phase 3   EUCTR2017-004554-42-DE   Belgium;France;Germany;Netherlands;Spain;Switzerland;Turkey;United Kingdom;
      -   Phase 3   EUCTR2017-004554-42-BE   Belgium;France;Germany;Netherlands;Spain;Switzerland;Turkey;United Kingdom;
TAS-205   
   Taiho Pharmaceutical Co., Ltd.
      2020   Phase 3   NCT04587908   Japan;
      2016   Phase 2   NCT02752048   Japan;
      2014   Phase 1   NCT02246478   Japan;
TETRACOSACTIDE ESACETATO   
   MALLINCKRODT ARD INC.
      2018   Phase 2   EUCTR2017-004139-35-IT   Bulgaria;Canada;Costa Rica;India;Ireland;Israel;Italy;Mexico;Poland;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States;
TETRACOSACTIDE HEXAACETATE   
   Mallinckrodt ARD Inc.
      2018   Phase 2   EUCTR2017-004139-35-ES   Argentina;Belgium;Bulgaria;Canada;Chile;Germany;Israel;Italy;Netherlands;Serbia;Spain;Turkey;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-004139-35-BG   Argentina;Belgium;Bulgaria;Canada;Chile;Germany;Israel;Italy;Netherlands;Serbia;Spain;Turkey;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-004139-35-BE   Argentina;Belgium;Canada;Chile;Germany;Israel;Italy;Netherlands;Serbia;Spain;Turkey;United Kingdom;United States;
Tacrolimus   
   FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
      2011   -   EUCTR2011-000176-33-IT   Italy;
Tadalafil   
   Cedars-Sinai Medical Center
      2017   Early Phase 1   NCT02653833   United States;
      2012   Phase 4   NCT02207283   -
      2012   -   NCT03076814   -
      2011   Early Phase 1   NCT01359670   United States;
      2010   Phase 4   NCT01070511   United States;
   Eli Lilly Japan K.K.
      -   Phase 3   JPRN-JapicCTI-142538   -
   Eli Lilly and Company
      2013   Phase 3   NCT01865084   Argentina;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Puerto Rico;Russian Federation;Spain;Taiwan;Turkey;United Kingdom;United States;
   University of Florida
      2021   Phase 2/Phase 3   NCT05195775   United States;
Tadalafil and Sildenafil   
   Cedars-Sinai Medical Center
      2012   Phase 1   NCT01580501   United States;
Taking of blood   
   University Hospital, Montpellier
      2010   -   NCT01596803   France;
Tamoxifen   
   Hadassah Medical Organization
      2016   Phase 1   NCT02835079   -
   University Hospital, Basel, Switzerland
      2018   Phase 3   NCT03354039   France;Germany;Netherlands;Spain;Switzerland;United Kingdom;
Tamoxifen 20mg Hexal® Filmtabletten   
   University of Basel Children's Hospital, Division of Neuropediatrics
      2020   Phase 3   EUCTR2017-004554-42-FR   Belgium;France;Germany;Netherlands;Spain;Switzerland;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004554-42-GB   Belgium;France;Germany;Netherlands;Spain;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2017-004554-42-DE   Belgium;France;Germany;Netherlands;Spain;Switzerland;Turkey;United Kingdom;
      -   Phase 3   EUCTR2017-004554-42-BE   Belgium;France;Germany;Netherlands;Spain;Switzerland;Turkey;United Kingdom;
Tehalose 30gr   
   Bioblast Pharma Ltd.
      2015   Phase 3   NCT02328482   Canada;
Temerit   
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      -   Phase 3   EUCTR2010-020047-12-FR   France;
Testosterone decanoate   
   The Newcastle upon Tyne NHS Hospitals Foundation Trust
      2015   Phase 3   EUCTR2015-003195-68-GB   United Kingdom;
Testosterone isocaproate   
   The Newcastle upon Tyne NHS Hospitals Foundation Trust
      2015   Phase 3   EUCTR2015-003195-68-GB   United Kingdom;
Testosterone phenylpropionate   
   The Newcastle upon Tyne NHS Hospitals Foundation Trust
      2015   Phase 3   EUCTR2015-003195-68-GB   United Kingdom;
Testosterone propionate   
   The Newcastle upon Tyne NHS Hospitals Foundation Trust
      2015   Phase 3   EUCTR2015-003195-68-GB   United Kingdom;
Tideglusib   
   AMO Pharma Limited
      2021   Phase 2/Phase 3   NCT05004129   Australia;Canada;New Zealand;United States;
      2021   Phase 2/Phase 3   NCT03692312   Australia;Canada;New Zealand;United Kingdom;United States;
      2016   Phase 2   NCT02858908   United Kingdom;
   AMO Pharma Ltd
      2018   Phase 2;Phase 3   EUCTR2016-004623-23-GB   Canada;United Kingdom;United States;
   AMO Pharma Ltd.
      2016   Phase 2   EUCTR2016-000067-16-GB   United Kingdom;
To be determined   
   Genethon
      2020   Phase 1;Phase 2;Phase 3   EUCTR2020-002093-27-FR   France;Israel;United Kingdom;United States;
Tranilast   
   Matsumura Tsuyoshi
      2018   -   JPRN-jRCTs031180038   Japan;
   National Hospital Organization Toneyama National Hospital
      2018   -   JPRN-UMIN000031965   Japan;
      2016   -   JPRN-UMIN000020580   Japan;
Translarna   
   PTC Therapeutics, Inc.
      -   Phase 2   EUCTR2020-000980-21-Outside-EU/EEA   United States;
Translarna 1000 mg granules for oral suspension   
   PTC Therapeutics, Inc.
      2018   Phase 3   EUCTR2017-001223-49-BG   Argentina;Australia;Brazil;Bulgaria;Canada;China;Hong Kong;India;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;Taiwan;Thailand;Turkey;United States;
      -   Phase 3   EUCTR2017-001223-49-PL   Argentina;Australia;Brazil;Bulgaria;Canada;China;Hong Kong;India;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;Taiwan;Thailand;Turkey;United States;
Translarna 125 mg granules for oral suspension   
   PTC Therapeutics, Inc.
      2018   Phase 3   EUCTR2017-001223-49-BG   Argentina;Australia;Brazil;Bulgaria;Canada;China;Hong Kong;India;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;Taiwan;Thailand;Turkey;United States;
      -   Phase 3   EUCTR2017-001223-49-PL   Argentina;Australia;Brazil;Bulgaria;Canada;China;Hong Kong;India;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;Taiwan;Thailand;Turkey;United States;
Translarna 250 mg granules for oral suspension   
   PTC Therapeutics, Inc.
      2018   Phase 3   EUCTR2017-001223-49-BG   Argentina;Australia;Brazil;Bulgaria;Canada;China;Hong Kong;India;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;Taiwan;Thailand;Turkey;United States;
      -   Phase 3   EUCTR2017-001223-49-PL   Argentina;Australia;Brazil;Bulgaria;Canada;China;Hong Kong;India;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;Taiwan;Thailand;Turkey;United States;
Treatment Phase Group 4   
   BioMarin Pharmaceutical
      2013   Phase 1/Phase 2   NCT01957059   Belgium;France;Italy;Netherlands;United Kingdom;
Trehalose   
   Bioblast Pharma Ltd.
      2017   Phase 2   NCT04226924   Canada;
Umbilical Cord Based Allogenic Mesenchymal Stem Cell   
   University of Gaziantep
      2015   Phase 1   NCT02484560   Turkey;
Umbilical Cord Mesenchymal Stem Cell   
   Acibadem University
      2013   Phase 1/Phase 2   NCT02285673   Turkey;
Umbilical Cord Mesenchymal Stem Cells   
   Allergy and Asthma Consultants, Wichita, Kansas
      2014   Phase 1   NCT02235844   United States;
VBP15   
   ReveraGen BioPharma, Inc
      2019   Phase 2   EUCTR2017-002704-27-GR   Australia;Belgium;Canada;Czech Republic;Germany;Greece;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;
   ReveraGen BioPharma, Inc.
      2019   Phase 2   EUCTR2017-002704-27-NL   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2019   Phase 2   EUCTR2017-002704-27-ES   Australia;Belgium;Canada;Czech Republic;Germany;Greece;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2019   Phase 2   EUCTR2017-002704-27-CZ   Australia;Belgium;Canada;Czech Republic;Germany;Greece;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2019   Phase 2   EUCTR2017-002704-27-BE   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-002704-27-SE   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-002704-27-GB   Australia;Belgium;Canada;Czech Republic;Germany;Greece;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-004462-26-GB   Australia;Canada;Israel;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-004263-38-GB   Australia;Canada;Israel;Sweden;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-004262-26-GB   Australia;Canada;Israel;Sweden;United Kingdom;United States;
Vamarolone   
   ReveraGen BioPharma Inc.
      2017   Phase 2   EUCTR2016-004263-38-SE   Australia;Canada;Israel;Sweden;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-004262-26-SE   Australia;Canada;Israel;Sweden;United Kingdom;United States;
   ReveraGen BioPharma, Inc.
      2017   Phase 2   EUCTR2016-004462-26-GB   Australia;Canada;Israel;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-004263-38-GB   Australia;Canada;Israel;Sweden;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-004262-26-GB   Australia;Canada;Israel;Sweden;United Kingdom;United States;
Vamorolone   
   ReveraGen BioPharma Inc.
      2018   Phase 2   EUCTR2017-003568-10-GB   Australia;Canada;Israel;Sweden;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-004263-38-SE   Australia;Canada;Israel;Sweden;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-004262-26-SE   Australia;Canada;Israel;Sweden;United Kingdom;United States;
   ReveraGen BioPharma, Inc.
      2022   Phase 2   NCT05185622   -
      2019   -   NCT03863119   Canada;Israel;United States;
      2018   Phase 2   NCT03439670   Australia;Belgium;Canada;Czechia;Germany;Greece;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-004462-26-GB   Australia;Canada;Israel;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-004263-38-GB   Australia;Canada;Israel;Sweden;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-004262-26-GB   Australia;Canada;Israel;Sweden;United Kingdom;United States;
Vamorolone 0.25 mg/day/day   
   ReveraGen BioPharma, Inc.
      2017   Phase 2   NCT03038399   Australia;Canada;Israel;Sweden;United Kingdom;United States;
      2016   Phase 2   NCT02760277   Australia;Canada;Israel;Sweden;United Kingdom;United States;
Vamorolone 0.25 mg/kg/day   
   ReveraGen BioPharma, Inc.
      2016   Phase 2   NCT02760264   Australia;Canada;Israel;Sweden;United Kingdom;United States;
Vamorolone 0.75 mg/day/day   
   ReveraGen BioPharma, Inc.
      2017   Phase 2   NCT03038399   Australia;Canada;Israel;Sweden;United Kingdom;United States;
      2016   Phase 2   NCT02760277   Australia;Canada;Israel;Sweden;United Kingdom;United States;
Vamorolone 0.75 mg/kg/day   
   ReveraGen BioPharma, Inc.
      2016   Phase 2   NCT02760264   Australia;Canada;Israel;Sweden;United Kingdom;United States;
Vamorolone 2.0 mg/day/day   
   ReveraGen BioPharma, Inc.
      2017   Phase 2   NCT03038399   Australia;Canada;Israel;Sweden;United Kingdom;United States;
      2016   Phase 2   NCT02760277   Australia;Canada;Israel;Sweden;United Kingdom;United States;
Vamorolone 2.0 mg/kg/day   
   ReveraGen BioPharma, Inc.
      2016   Phase 2   NCT02760264   Australia;Canada;Israel;Sweden;United Kingdom;United States;
Vamorolone 6.0 mg/day/day   
   ReveraGen BioPharma, Inc.
      2017   Phase 2   NCT03038399   Australia;Canada;Israel;Sweden;United Kingdom;United States;
      2016   Phase 2   NCT02760277   Australia;Canada;Israel;Sweden;United Kingdom;United States;
Vamorolone 6.0 mg/kg/day   
   ReveraGen BioPharma, Inc.
      2016   Phase 2   NCT02760264   Australia;Canada;Israel;Sweden;United Kingdom;United States;
Viltolarsen   
   NS Pharma, Inc.
      2021   Phase 4   NCT04687020   Canada;United States;
      2021   Phase 3   NCT04768062   Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Spain;Turkey;
      2021   Phase 2   NCT04956289   Italy;Russian Federation;Spain;Turkey;United States;
      2020   Phase 3   NCT04060199   Australia;Canada;Chile;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2008   -   NCT04337112   -
Vit C Vit E Zn Se   
   University Hospital, Montpellier
      2010   -   NCT01596803   France;
WVE-210201   
   WAVE LIFE SCIENCES USA INC
      2018   Phase 1   EUCTR2017-002686-21-IT   Belgium;Canada;France;Italy;Netherlands;United Kingdom;United States;
   Wave Life Sciences Ltd.
      2019   Phase 1   EUCTR2018-000975-34-NL   Belgium;Canada;France;Italy;Netherlands;United Kingdom;United States;
      2018   Phase 1   NCT03508947   Belgium;Canada;France;Italy;Netherlands;United Kingdom;United States;
      2018   Phase 1   EUCTR2018-000975-34-GB   Belgium;Canada;France;Italy;Netherlands;United Kingdom;United States;
      2018   Phase 1   EUCTR2018-000975-34-BE   Belgium;Canada;France;Italy;Netherlands;United Kingdom;United States;
      2018   Phase 1   EUCTR2017-002686-21-NL   Belgium;Czech Republic;Denmark;France;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2018   Phase 1   EUCTR2017-002686-21-GB   Belgium;Canada;France;Italy;Netherlands;United Kingdom;United States;
      2018   Phase 1   EUCTR2017-002686-21-BE   Belgium;Canada;France;Italy;Netherlands;United Kingdom;United States;
      -   Phase 1   EUCTR2018-000975-34-FR   Belgium;Canada;France;Italy;Netherlands;United Kingdom;United States;
      -   Phase 1   EUCTR2017-002686-21-FR   Belgium;Czech Republic;Denmark;France;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
   Wave Life Sciences UK Limited
      2019   Phase 2;Phase 3   EUCTR2018-004009-22-SE   Australia;Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-004009-22-IT   Australia;Belgium;Canada;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-004009-22-GB   Australia;Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-004009-22-CZ   Australia;Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-004009-22-BE   Australia;Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2018-004009-22-PL   Australia;Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2018-004009-22-NL   Australia;Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2018-004009-22-FR   Australia;Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2018-004009-22-DE   Australia;Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States;
WVE-210201 (suvodirsen)   
   Wave Life Sciences Ltd.
      2019   Phase 2/Phase 3   NCT03907072   Belgium;Canada;Czechia;France;Italy;Sweden;United Kingdom;United States;
WVE-N531   
   Wave Life Sciences Ltd.
      2021   Phase 1/Phase 2   NCT04906460   Canada;United Kingdom;
Xeomin   
   Rigshospitalet
      2014   Phase 2   EUCTR2014-002210-23-DK   Denmark;
metformin and 7.5 g L-citrulline daily p.o.   
   University Hospital, Basel, Switzerland
      2013   Phase 3   NCT01995032   Switzerland;